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ABSTRACT 
DETECTION AND CHARACTERISATION OF METALLO BETA 
LACTAMASE PRODUCTION IN PSEUDOMONAS AERUGINOSA BY 
PHENOTYPIC AND MOLECULAR METHODS FROM CLINICAL 
ISOLATES IN A TERTIARY CARE HOSPITAL. 
 
INTRODUCTION: 
 P.aeruginosa is an opportunistic pathogen associated with a range of 
nosocomial infections. It flourishes as a saprophyte, with innate resistance to 
many antibiotics. In addition to its innate resistance, acquired resistance is 
particularly associated with indiscriminate use of antimicrobials. Carbapenams 
is the last resort drug used against this organism isolated from patients. 
Resistance to carbapenams has emerged by various mechanisms; one growing 
factor leading to the resistance is the production of metallo beta lactamases. 
With worldwide increase in the occurrence and dissemination of MBLs, early 
detection is crucial, the benefits of which include timely implementation of 
strict infection control practices and treatment with alternative antimicrobials. 
OBJECTIVE: 
  To detect the prevalence of MBL production in Pseudomonas 
aeruginosa isolates in Tirunelveli Medical College. 
 To detect the MBL production in Pseudomonas aeruginosa isolates by 
phenotypic and genotypic methods. 
 To evaluate various phenotypic methods in the detection of MBL. 
METHODS AND MATERIALS: 
 This study will be conducted in the Department of Microbiology in 
Tirunelveli medical college hospital after approval from the institutional ethical 
committee. A total of 100 consecutive non repetitive clinical isolates of 
P.aeruginosa are subjected to three different phenotypic methods such as 
combined disc test (CDT), double disc synergy test (DDST), MBL E test using 
Meropenem and confirmed genotypically by RT-PCR for the presence of bla 
IMP and bla VIM gene. 
RESULTS: 
 Out of 100 P.aeruginosa isolates, 21 were resistant to Meropenem. Out of 
21 Meropenem resistant P.aeruginosa isolates 14 were detected as MBL 
producer by CDT, 12 and 10 were detected as MBL producer by DDST and 
MBL E test respectively. The PCR detected 10 isolates as MBL producer and 
all of them were positive for bla VIM gene and no bla IMP gene was detected 
in any of the isolates.  
CONCLUSION: 
 This study shows that DDST is the simple and cost effective method in 
the detection of MBL and it should be confirmed with the MBL E test if PCR is 
not available in the clinical laboratory settings. 
Keywords: P.aeruginosa, Meropenem, MBL, Phenotypic methods, PCR 
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1. INTRODUCTION 
 
Pseudomonas aeruginosa are aerobic non-spore-forming, gram 
negative rods motile with the help of one or more polar flagella can grow 
normally using minimal nutritional components. Many of them are 
saprophytes and others are opportunistic pathogens of humans. 
Pseudomonas aeruginosa has been found in many things used in 
laboratories and medical practice.  
 P.aeruginosa can survive strict environmental conditions and shows 
intrinsic resistance towards many antimicrobials which facilitate the 
organism to survive in the hospital setting. Within the hospital, the 
colonization of P. aeruginosa is seen mostly in the moist surfaces of 
patients on the axilla, ear, and perineum. It is also isolated from other moist 
environments such as in water sinks and drains, toilets and showers. The 
equipment used in the hospital that comes in contact with water, such as 
mops, respiratory ventilators, cleaning solutions can also form the sources 
of P. aeruginosa
1
. 
Hence it is the most common opportunistic pathogen that requires 
compromised host defense to establish infection and is considered as the 
leading cause of hospital acquired infections. In normal individuals 
infection is usually associated with the disruption or bypass of the defense 
mechanism provided by the epidermis for instance burns, punctured 
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wounds, usage of contaminated needles and trauma to the eyes with 
contaminated contact lenses which results in infections of the skin and bone, 
septicemia, wound and eye infections
2
.
  
 
For immunocompromised patients the infections due to P.aeruginosa 
are severe and life threatening. In cystic fibrosis patients these organisms 
have predilection to the respiratory tract and cause severe pneumonia. It 
may cause invasive malignant otitis externa in diabetic patients and in any 
condition which results in leukopenia, P.aeruginosa assumes an 
opportunistic pathogenic role
3
. There is also a problem of community 
acquired pseudomonas infection due to the exposure to the moist surfaces 
like swimming pools and other types of tubs
4
. 
As it is the leading cause of nosocomial infections and shows intrinsic 
and acquired resistance towards many antimicrobials, it increases the 
morbidity and mortality of the hospitalized patients
5
. Hospital acquired 
infections due to multidrug resistant P. aeruginosa have been related with 
increased hospital expenses and poorer clinical outcomes
6
. The resistance 
pattern in P. aeruginosa  includes reduced permeability of the cell wall due 
to loss of OprD porin ,extracellular chromosomal and plasmid-mediated 
enzyme production like Metallo β-lactamases, aminoglycosidases and 
cephalosporinases, modification in antibiotic-binding protein sites, the up-
regulation of an active efflux mechanism which drives out antibiotic from 
the cell
7
. Although the antibiotic resistance in P.aeruginosa is caused by 
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multiple mechanisms, one major factor leading to resistance is the 
production of metallo beta lactamases. Metallo beta Lactamases (MBL) 
hydrolyses all beta lactams including carbapenems except Aztreonam. 
The prevalence of MBL producing P. aeruginosa ranges from 8 – 
14% in various parts of India
8
. The resistance to the last resort drug 
Carbapenem due to the production of MBL is the emerging problem to the 
clinicians in treating the P. aeruginosa infections. Hence there should be 
urgency in detecting the resistance in P. aeruginosa in clinical laboratory. 
There are different methods to detect phenotypically the production of 
the MBL production in the clinical laboratory. But there are no formulated 
guidelines from the CLSI for the detection of the metallo beta lactamase 
producing P. aeruginosa.  The various phenotypic methods that are 
available to detect the MBL include, combined disc test (CDT), double disc 
synergy test (DDST), MBL E test, Modified hodge test. The genotypic 
method to detect and confirm MBL is the PCR (Polymerase Chain 
Reaction) which identifies the common genes like IMP and VIM encoding 
for MBL production. The molecular detection of the metallo beta lactamase 
using PCR is available only in the reference center is the limitation 
regarding the gene detection. 
Early detection is critical and the benefits of which include timely 
execution of strict infection control practices, formulating an effective 
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antibiotic strategy to prevent the spread of these MBL producing strains, 
and treatment with alternative antimicrobials. 
Hence the present study is intended to detect the presence of MBL 
producing P. aeruginosa and the susceptibility pattern of these strains to 
other antibiotics in clinical isolates in our hospital using both phenotypic 
and genotypic tests. All the Pseudomonas aeruginosa isolates are subjected 
to three different phenotypic methods such as combined disc test (CDT), 
double disc synergy test (DDST) and MBL E test using Meropenem disc 
and EDTA as chelator to find out their effectiveness in the detection of the 
production of MBL. The Meropenem disc is used to perform the phenotypic 
tests, as stated in the CLSI guidelines (2013) that the Imipenem disc 
performs poorly as a screen for carbapenemases. The PCR is also performed 
to check the presence of blaIMP and blaVIM gene responsible for the 
production of MBL.    
  
 
 
 
 
 
 
 
5 
 
 
 
2. AIMS AND OBJECTIVES 
 
 To detect the prevalence of MBL production in Pseudomonas 
aeruginosa isolates in Tirunelveli Medical College. 
 To detect the MBL production in Pseudomonas aeruginosa isolates 
by phenotypic and genotypic methods. 
 To evaluate various phenotypic methods in the detection of MBL. 
 To assess antibiotic susceptibility pattern of Pseudomonas 
aeruginosa. 
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3. REVIEW OF LITERATURE 
 
3.1 HISTORY 
Pseudomonas aeruginosa first documented as the source of „blue pus‟ 
in wounds and hence named Bacillus pyocyaneus by Gessard. The name 
was altered by S edillot in to Pseudomonas pyocyanea in 1850. Luke noted 
the rod shaped bacteria in the blue green pus from the surgical dressings and 
later Schroeter named it Pseudomonas aeruginosa in 1872. Osler in 1925 
suggested that this organism is said to invade the damaged tissues rather the 
healthy tissue
1
.  P. aeruginosa produces the pigment pyocyanin that gives 
rise to a typical green colony on solid media. The name aeruginosa was 
derived from the green hue seen in colonies of clinical isolates. 
   In 1960s P. aeruginosa emerged as a major human pathogen due to 
its ability to cause infections in immunocompromised and burn patients and 
in those who were in modern medical equipment.  Since then, P. aeruginosa 
has become one of the most severe causes of nosocomial infections, 
particularly in the lung, wound infections, blood and urinary tract
4
. 
3.2 TAXONOMY: 
 Palleroni divided the Pseudomonas into five ribosomal RNA groups 
based on rRNA-DNA studies. Based on phenotypic characteristics the 
pseudomonads are separated into 7 groups by Gilardi namely fluorescent, 
stutzeri, alcaligenes, pseudomallei, acidovarans, facilis-delafieldii and 
7 
 
diminuta. The name Pseudomonas was reserved for rRNA group I, which 
included Pseudomonas aeruginosa. The species of Pseudomonas can be 
subdivided into two groups, the fluorescent and the non-fluorescent species. 
The new edition of Bergey‟s Manual of systematic bacteriology includes 
about 65 species in Pseudomonas
1
. 
RNA Group I: 
Flouresent Group  
P. aeruginosa  
P. fluorescence  
P. putida  
Stutzeri Group  
P. stutzeri  
P. mendocina  
CDC group Vb-3  
Alcaligenes Group  
P. alcaligenes  
P. pseudoalcaligenes  
Pseudomonas species group-1 
Fluorescent Group:  
 In this group all the species produce a water soluble pigment called 
pyoverdin that fluoresces blue-green under long wavelength ultraviolet 
light. Although all three members of this group produce Pyoverdin, only one 
8 
 
species, Pseudomonas aeruginosa, produces the distinctive blue pigment 
pyocyanin which is water soluble. Pseudomonas aeruginosa is the 
pseudomonad most frequently recovered from clinical specimens
9
. 
3.3 MORPHOLOGY:  
 Pseudomonas aeruginosa are aerobic gram negative rods. They are 
non-spore-forming, straight or slightly curved rods measuring 0.5 to 1.0 by 
1.5 to 5.0 µm. They are motile, with single polar flagella.  
3.4 CULTURAL CHARACTERISTICS: 
 
 Pseudomonas aeruginosa is nutritionally adaptable and grows readily 
on most common diagnostic media. They have a strictly aerobic respiratory 
metabolism and uses oxygen as the terminal electron acceptor. The nitrate 
can also be used as an alternative electron acceptor and grows anerobically. 
They are oxidase positive, catalase positive. The growth can occur in the 
temperature between 5 and 42
0
 C and the optimum temperature is 37
0
C. The 
optimum pH ranges from 7.4-7.6. The cultures produce a characteristics 
grape or earthy like smell of acetaminophenone. 
 On nutrient agar, six distinct colonial types of Pseudomonas 
aeruginosa are seen
10
. 
Type I: Large rough colonies surrounded by serrated skirts of growth. 
Type II: Coliform like, Small, smooth domed colonies. 
Type III: Small rough colonies 
Type IV: Small rugose colonies 
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Type V: Mucoid Alginate producing colonies 
Type VI: Dwarf colonies. 
 The type 2 colonies are most commonly isolated from the 
environmental sources and the type 5 is frequently isolated from respiratory 
secretions from cystic fibrosis patients.  
 On blood agar, a flat spreading colony with serrated edges often 
shows metallic sheen. It produces beta hemolytic colonies. 
 On Mac-conkey agar, colourless colonies which do not ferment 
lactose are produced. 
 It forms a dense turbidity with a surface pellicle in the broth. 
3.5 PRODUCTION OF PIGMENTS:  
 The characteristic feature of the P. aeruginosa is the production of 
pigments.   These pigments diffuse into the culture media as they are water-
soluble. 
Types of pigments produced by P. aeruginosa: 
o Pyocyanin  
o Pyorubin  
o Pyomelanin  
o Pyoverdin  
 Pyocyanin is the blue phenazine pigment which is characteristic of 
Pseudomonas aeruginosa. It is also enhanced by the addition of 10% of egg 
white to the complex media. Pyocyanin is water soluble, and the colour 
10 
 
depends on the pH. The presence of this pigment and a characteristic fruity 
odor are the valuable characters for the preliminary identification. 
Pyorubrin is a red pigment and the addition of glutamate enhances its 
production. Pyomelanin is a brown pigment which is produced from 
aromatic amino acids such as tyrosine or phenylalanine. The pyoverdin is of 
three types and it enhances the virulence of the organism. This pigment is 
used for the purpose of typing (siderotyping). 
Some of the strains produce pigments like phenazine-1-carboxylate, 
dihydroxyphenazine-1-carboxylic acid, chlororaphin and oxychlororaphin.  
3.6 BIOCHEMICAL REACTIONS: 
  Oxidase positive, does not ferment carbohydrates, glucose is utilized 
oxidatively forming acid only.  It appears inert. Indole and H2S are not 
produced.  
Voges – Proskauer and Methyl red reactions are negative. Nitrates are 
reduced to nitrites and to gaseous nitrogen.  
  Catalase, oxidase and Arginine dihydrolase tests are positive. Lactose, 
sucrose and mannitol are not fermented but xylose is fermented. 
On Triple sugar iron agar alkaline slant and alkaline butt are produced 
with no gas and H2S production. 
Citrate is utilized and urea is not hydrolysed. Phenyl pyruvic acid is 
not produced and the gelatin is liquefied.  
11 
 
The selective medium for the isolation of Pseudomonas aeruginosa is 
the cetrimide agar in which the cetrimide acts as detergent which inhibits 
most bacteria and enhances the pigment production. 
3.7 Minimum requirements for the definitive diagnosis of 
P.aeruginosa
9
:
 
 
 Gram negative rod 
 Oxidase positive 
 Typical smell i.e fruity grape like odour 
 Recognizable colony morphology 
 Large green pigmented colonies with metallic sheen and 
beta hemolysis on blood agar. 
 On Mac conkey agar, colourless, non-lactose fermenting, 
colonies 
3.8 TYPING METHODS: 
 
 The typing methods are used mainly for epidemiological purposes. 
There are three methods of typing namely, bacteriocin typing, serotyping 
and DNA restriction analysis. 
3.8.1 Bacteriocin typing:  
 Bacteriocins are the proteins produced by a strain which is lethal to 
other strains of the similar bacteria. Pyocins are the bacteriocins produced 
by P.aeruginosa. There are three types of pyocins namely R, F, and S are 
12 
 
produced by P.aeruginosa. About 90% of the P.aeruginosa strains produce 
pyocins
10
. 
3.8.2 Serotyping: 
 The serotyping is done based on the reaction of heat stable O-antigen 
with a set of antisera. The antisera are prepared against the Pseudomonas 
cell suspensions. 
3.8.3 DNA restriction analysis: 
 The endonucleases are used in the restriction analysis. Pseudomonas 
is rich in G+C pairs, and after digestion they will give more fragments. The 
separation is usually done by electrophoresis. 
3.9 EPIDEMIOLOGY:  
 The primary habitat of P. aeruginosa is the environment and it is 
found in water, soil, and various types of vegetation.  P. aeruginosa was 
isolated from the throat and stool in 7% and 24% respectively of healthy 
humans
4
.  P. aeruginosa can grow with minimal nutritional requirements 
such as in distilled water and can tolerate temperatures as high as 45
0
C to 
50
0
C. It grows even in antiseptic solutions with the help of divalent cations 
such as carbon.  The minimal nutritional requirement for its growth 
contributes to its ecological success and its major role as opportunistic 
pathogen. Moisture is the serious factor which is associated with the human 
colonization. It colonizes in moist areas like axilla, perineum and ear. 
External sources of infection can be various materials, such as plants and 
13 
 
flowers, brought by visitors or health personnel that colonize the hospital 
environment like respiratory instruments, ventilators and in many equipment 
used in clinical laboratories and medical practice
4
.  
P. aeruginosa skin infections (Jacuzzi) are related to use of hot tubs 
and swimming pools are the common clinical presentations of community-
acquired infection. The community- acquired P. aeruginosa infection is 
considered a minor problem when compared to the nosocomial infection. 
Gastrointestinal (GI) colonization occurs secondary to the use of 
antibiotics that disrupt the normal microbial flora of the GI tract which 
sometimes can lead to aspiration results in the respiratory tract colonization.  
The extended-wear of contact lenses has increased risk of P. 
aeruginosa ulcerative keratitis due to the presence of the organism in the 
lens solution.  
Patients with burn wounds are at high risk for P. aeruginosa infection 
due to the loss of physical barrier of the intact dermis. Patients, who receive 
mechanical ventilation, become colonized with P. aeruginosa results in 
pneumonia known as ventilator associated pneumonia.   
O.Oncul, et al from Iraq in his studies reported that the rate of 
infection with the P.aeruginosa is increased in burn patients
11
. 
The National Nosocomial Infections Surveillance system 1986-2003 
recorded P. aeruginosa as the 2
nd
 common cause of pneumonia, third most 
common cause of urinary tract infections. P. aeruginosa is a common cause 
14 
 
of nosocomial urinary tract infection that represents 7 % of all nosocomial 
infections. Community acquired urinary tract infections are not commonly 
caused by P. aeruginosa
12
. 
 In the United States, the health care associated pneumonias 
accounted for about 18.1%, 9.5% of surgical site infections and 3.4% of 
septicemia in intensive care units are due to P. aeruginosa in the year 2003
4
.  
Invasive P. aeruginosa infection usually precedes a period of 
colonization in 50% of infected patients with an underlying risk factor for 
infection. 
 In hospitals the most common opportunistic pathogen is P. 
aeruginosa.   This infection is a leading cause of morbidity and mortality of 
the patients.  This increases the problem in the treatment of this infection.  
Elizabeth B Hirsch et al reported that in a study with 136 patients, the 
mortality rate increases with the inappropriate and delay in the treatment of 
MDR P. aeruginosa
6
. 
3.10 PATHOGENESIS:  
 P. aeruginosa commonly requires a break in defenses to initiate 
infection. In burns and wound infections, P. aeruginosa grows better in 
dead or poorly perfused tissue, to allow it to seed the blood and devastate 
the immunity of the host
4
.  
The normal healthy eye is resistant to P. aeruginosa infection, but 
when the physical integrity of the corneal epithelium is broken, P. 
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aeruginosa turn out to be a major pathogen. The fundamental mechanism 
related to increased host susceptibility to P. aeruginosa infection is loss of 
tissue integrity.  
Adherence of the organism to the host tissue is the first step in 
infection and it is mediated by adhesins like pili, flagella, and the 
extracellular polysaccharide slime which bind to the receptors. The 
receptors include sialic acid and N acetyl glucosamine and the attachment is 
enhanced by loss of surface fibronectin, which explains in part the 
susceptibility for debilitated persons. Entry of P. aeruginosa in the host 
occurs by the oral or respiratory route.  
Host tissues provide a stressed environment for the organism with 
reduced availability of nutrients, oxygen, and other growth factors.  The 
response of the microbe to the in vivo environment and the antimicrobial 
response of the host regulate the progression from colonization to infection 
and the disease. The virulence factors such as exotoxin A, exotoxin S, and 
elastase are directly injected into host cells by a special contact secretion 
system
3
.  
The dissemination from burn wounds is associated with Exoenzyme S 
which destructs the cytoskeleton of the cell. The elastase in the 
Pseudomonas attacks the elastin in the lung and blood vessels. The 
hemorrhagic destruction of the walls of blood vessels is the histologic 
feature of Pseudomonas infection.  
16 
 
The ability to form biofilms and the mechanism of quorum sensing 
plays an important role in the pathogenesis of the disease. The P. 
aeruginosa can grow anaerobically if nitrate is present and it is the 
significant pathogen of implanted medical devices such as intravenous 
catheters, orthopedic implants on which the organism can colonize and form 
a biofilm which disseminate systemically. The major components of a 
biofilm are a matrix composed of polysaccharide called a glycocalyx.  
3.11 VIRULENCE FACTORS
9
: 
 P. aeruginosa produces numerous virulence factors in the form of 
enzymes and toxins that is responsible for its complex pathogenesis. 
 Exotoxin A (ETA) is the most toxic extracellular enzymes produced 
by P. aeruginosa. It inhibits the protein synthesis which is similar to that of 
the diphtheria toxin. 
 Alkaline proteases and elastase cause vascular lesions, necrosis and 
shedding of respiratory epithelial cells. These two metallo protease enzymes 
are inhibited by chelating agents. 
 Alginate is a capsular polysaccharide which is helpful in the 
adherence of the bacteria to the lung epithelium and forms biofilm. It resists 
phagocytosis and opsonisation killing by the host cells. 
 Pili which is responsible for the twitching motility, helps in adherence 
of the organism to GM-1 ganglioside. It also takes part in the biofilm 
formation. The siderophore receptors are present in the outer membrane 
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which enhances the microbial growth by providing iron as a source. It also 
has efflux pumps to remove antibiotics. The pyoverdine and pyochelin are 
the two siderophores produced by the Pseudomonas aeruginosa. The heat-
labile phospholipase C and heat-stable rhamnolipid are the two hemolysins 
produced by P. aeruginosa. 
 There are three types of proteases secreted by the organism namely 
LasA protease, LasB elastase and alkaline protease which degrades host 
immune effectors like antibody and complement. Ferripyochelin and 
Pyocyanin are the secreted oxidative factors which produce reactive oxygen 
radicals that disrupt epithelial cell function and cause oxidative damage to 
tissues. It also damages the respiratory ciliary activity. 
Lipopolysaccharide is endotoxic and antiphagocytic which causes 
sepsis syndrome, DIC and metabolic abnormalities. 
Neuraminidase is the virulent enzyme that facilitates the binding of 
pili by removing the sialic acid residues from GM-1 ganglioside receptors. 
The Phospholipase C destructs the cytoplasmic membrane and pulmonary 
surfactant and results in the respiratory infection.  The other factors like 
Leucocidin, inhibits the function of lymphocyte and neutrophils. The 
enterotoxin causes diarrhea. 
The virulence factors depend upon the site and nature of infection. 
 Proteases have a major role in corneal ulceration. 
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 Exotoxin and elastases are responsible for burns infections and 
septicemia. 
 The Quorum sensing molecules and Alginate are related to the 
biofilm formation in chronic pulmonary colonization. 
 Pyochelin and pyoverdin are the bacterial siderophores that 
enhances the virulence. 
In Cystic Fibrosis, the mucoid colonies of P. aeruginosa strains are due to 
the increased production of a polysaccharide polymer known as Alginate. 
The pulmonary infection can also be caused by the virulence of flagella and 
fimbriae. The non pilus adhesins of P. aeruginosa adhere to the mucous 
surfaces of the lungs and increase the pathogenicity. The Pyocyanin pigment 
induces the release of interleukin-8 in cystic fibrosis that increases the 
intracellular oxidant stress. 
3.11.1 Quorum Sensing
1
: 
The communication system between the cells population in which the 
regulation of transcription of genes occurs only when a critical mass of the 
cell is achieved. The system of quorum sensing (QS) allows the organism to 
communicate with each other after the critical mass is reached. 
The low-molecular-weight mediators of the quorum sensing response 
are synthesized and secreted. These molecular mediators are called auto 
inducers (AIs). The auto inducers diffuse through the cells of the bacterial 
community that induce gene transcription and virulence factor production. 
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There are three major interrelated quorum sensing systems are known to 
exist in P. aeruginosa.  These include the las, rhl, and Pseudomonas 
quinolone system (PQS).  
The expression of several virulence factors, including elastase and 
rhamnolid are regulated by the quorum-sensing system of P. aeruginosa. 
3.11.2 Biofilm as a mechanism of resistance
4
: 
The other mechanism that involves in the virulence is the biofilm 
formation that protects the organism from many antibiotics. Biofilm plays a 
major role in the pathogenesis of chronic infections such as osteomyelitis 
and cystic fibrosis.  
The mechanism of resistance behind the biofilm formation include 
quorum sensing , decreased diffusion of antibiotics through the matrix 
polysaccharide alginate , synthesis of glucans that specifically bind 
antibiotics , and anaerobic growth of biofilm bacteria. 
3.12 CLINICAL MANIFESTATIONS: 
 P. aeruginosa can produce any of the opportunistic infections. It 
causes infections in burns and wound, urinary tract, skin, eye, ear and 
respiratory infections which may progress to septicemia.  
 It may cause post-operative wound infections very commonly.  A 
study by Prabhat ranjan et al on surgical wound infections reported that the 
most common (29.6%) bacteria isolated was P. aeruginosa
13
. Anupurba et 
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al in a similar study concluded that P. aeruginosa was isolated in 32% out 
of 940 clinical isolates from wound infections
14
.  
 It is the common pathogen isolated in burn patients. Kalantar E, et al 
in his studies reported that swab from 176 burn patients, 100 swabs were 
turned to be P. aeruginosa
15
. 
 Rajput A, et al, 2007 in his study with 154 isolates from burn patients, 
the most common organisms isolated were Pseudomonas aeruginosa 
(55%)
16
.  
 In 1959-1963 the burn wound sepsis is the major cause of death in   
60 % of the burns patients in US army
5
. In a study conducted in Iran by 
Leila Azmi et al said that the burn patients are more vulnerable to the 
colonization of P. aeruginosa in the environment. Among 717 samples 
taken from the burns, P. aeruginosa  was isolated from 324 specimens. The 
mortality rate was 12% and all the patients who died had one culture 
positive with P. aeruginosa 
17
.  
 Pseudomonas aeruginosa is very invasive that frequently causes 
severe damage to the tissues in diabetic foot ulcers. Tamil Selvi 
Sivanmaliappan et al in their study showed that about 14.3 % of the pus 
collected from the diabetic foot ulcers are P. aeruginosa
18
. P. aeruginosa is 
also a common cause of otitis externa, including “swimmer‟s ear” and 
“malignant” otitis externa in diabetic patients. 
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 Pseudomonas aeruginosa is responsible for nosocomial pneumonia 
especially among patients who have been hospitalized in intensive care units 
and under mechanical ventilation. Ventilator associated pneumonia (VAP) 
caused by Pseudomonas aeruginosa remains a severe and dreaded 
complication 
19
. 
 In a study by Mayank Dwivedi et al showed that VAP was the most 
common infection among the hospital acquired infections due to 
Pseudomonas aeruginosa and it was about 63 (31.5%) patients out of 200 
patients admitted in the ICU
20
.  
Crouch Brewer et al revealed that about 38% of the deaths are 
directly associated with the P. aeruginosa  in the ventilated patients. Septic 
shock and multiple organ dysfunction syndromes are the main causes of 
death among these VAP patients
21
. 
It also causes osteomyelitis in environmentally contaminated wounds 
of compound fractures or nail puncture wounds of the foot and also in 
prosthesis. The etiologic agent in 4 to 6% of infected orthopedic devices 
was Pseudomonas aeruginosa
22
. 
P. aeruginosa causes pneumonia particularly in patients with 
neutropenia. Pulmonary infection in cystic fibrosis is a chronic infection 
with alveolar necrosis, vascular invasion, infarcts and bacteremia. 
 The organism can cause conjunctivitis, keratitis, or endophthalmitis 
when introduced into the eye by trauma. The people who wear contact 
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lenses for an extended period are at increased risk of P. aeruginosa 
ulcerative keratitis. Cheng KH et al in his study reviewed about 96 cases of 
microbial keratitis that wear contact lenses for a long period and stated that 
P. aeruginosa was the commonest organism isolated
23
.  
In P. aeruginosa bacteremia, cutaneous papules develop into necrotic 
ulcers called ecthyma gangrenosum due to the destruction of blood vessel 
walls by the organism. CNS infections are rare and are always secondary to 
head injury or surgical procedure
4
. 
3.13. TREATMENT OF INFECTIONS DUE TO PSEUDOMONAS 
AERUGINOSA: 
 P. aeruginosa is usually resistant to penicillin, ampicillin, 
tetracycline, chloramphenicol, sulfonamides, cephalothin, and the earlier 
aminoglycosides like streptomycin, kanamycin. The antibiotics with 
antipseudomonal activity include the newer aminoglycosides like 
gentamicin, tobramycin, and amikacin, ticarcillin, ureidopenicillins, third 
generation cephalosporins such as ceftazidime, cefepime and cefoperazone, 
quinolones, aztreonam and the carbapenems.  
 Carbapenems have a wider spectrum of activity against multiresistant 
P. aeruginosa isolates and are used as reserve drugs for the treatment of 
infections. 
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3.14. MECHANISM OF ANTIBIOTIC RESISTANCE: 
 This microorganism very often possesses various mechanisms to 
express the resistance towards almost all the available antibiotics. 
3.14.1. Penicillins and Cephalosporins
24
: 
The carbenicillin is semi-synthetic penicillin and was introduced in 
1967 against P. aeruginosa. It has a carboxyl group in their side chains in 
order to alter the susceptibility to inactivating enzymes like β-lactamases 
and to enhance the effectiveness of antibacterial activity and the 
pharmacological properties of the drug. 
The first cephalosporins obtained from Cephalosporium acremonium 
and the active nucleus is 7-aminocephalosporanic acid, which consists of a 
β-lactam ring fused to a dihydrothiazine ring. The side chains are added to 
produce semisynthetic compounds with wider range of antibacterial activity. 
Cephalosporins are classified by generations based on general 
features of their antibacterial activity. The first and second generation 
cephalosporins are not active against the Pseudomonas aeruginosa. The 
ceftazidime and cefoperazone which belongs to the third generation 
cephalosporins have potent action against Pseudomonas aeruginosa. 
3.14.1.1. Mechanism of Action: 
Penicillins and cephlosporins inhibit bacterial growth by interfering 
with the transpeptidation reaction of bacterial peptidoglycan synthesis 
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which is a heteropolymeric component of the cell wall that gives stability to 
the organism. 
3.14.1.2. Mechanism of Resistance
7
: 
 P. aeruginosa possesses an inducible chromosomal AmpC β-
lactamase which causes resistant to penicillins, first generation and second-
generation cephalosporins. It also confers resistance to cefotaxime and 
ceftriaxone. 
 The other mechanism of resistance to the β-lactam antibiotics is the 
presence of multiple efflux pumps in P. aeruginosa that can result in 
expulsion of β -lactams. The acquired resistance is by the β-lactamases that 
are encoded in plasmids, on transposons or integrons which confer 
resistance to antipseudomonal penicillins, ceftazidime and cefipime. 
3.14.2 β-LACTAMASE INHIBITORS: 
 The molecules that inactivate the enzyme β-lactamase, and thereby 
prevent the destruction of β lactam antibiotics are called β-lactamase 
inhibitors. They are mostly active against plasmid-encoded β-lactamases 
that hydrolyze ceftazidime and cefotaxime. Clavulanic acid, sulbactam, 
tazobactam are the common β-lactamase inhibitors used against P. 
aeruginosa infections now a day. 
3.14.3 MONOBACTAMS
7
: 
 Monobactam binds to penicillin binding protein 3 (PBP 3) of gram-
negative aerobic organism like P. aeruginosa, thus inhibiting the bacterial 
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cell wall synthesis. Like carbapenems it is also stable against commonly 
occurring plasmid and chromosomally mediated β-lactamases. Aztreonam is 
the only monobactam available for clinical use. 
3.14.4 Resistance Mechanism of Aminoglycosides, Quinolones and other 
antibiotics
7
: 
 There are various mechanisms responsible for the intrinsic resistance 
of the organism towards many antibiotics. The impermeability mutation 
due to the loss of the OprD porin that results in the resistance of 
aminoglycosides, quinolones and colistin. The aminoglycoside-modifying 
enzymes often encoded on transposons and integrons result in various 
combinations of resistance to gentamicin, tobramycin or amikacin.  
These enzymes also carry resistance determinants for other classes of 
antibiotics such as sulfonamides, β-lactams and chloramphenicol. Along 
with the impermeability mutations these Aminoglycoside-modifying 
enzymes result in the broad-spectrum aminoglycoside resistance. It has been 
described that the broad-spectrum aminoglycoside resistance is due to a 
gene rmtA. 
The intrinsic mechanism which includes efflux pump systems 
mediated by some regulatory genes can cause expulsion of β -lactams, 
fluoroquinolones, macrolides, sulfonamides, chloramphenicol, tetracycline, 
and trimethoprim.  
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The overproduction of the efflux pump is due to the upregulation of 
the mexR gene which can cause resistance to antibiotics such as quinolones, 
penicillins, cephalosporins and aztreonam. 
3.14.5 CARBAPENEMS: 
Carbapenems are distinctive of all classes of β-lactam antibiotics. 
They have a hydroxyl ethyl side chain at position 6 and lack sulphur or 
oxygen atom in the nucleus. 
3.14.5.1 MECHANISM OF ACTION OF CARBAPENAMS: 
 Carbapenems bind to penicillin binding protein (PBP 1 and PBP 2) of 
gram-negative and gram-positive bacteria. They cause elongation of cell and 
lysis. They are not hydrolyzed by most plasmid or chromosomally mediated 
β-lactamases. The peculiar stereochemistry of the hydroxyethyl side chain 
gives stability against β-lactamases. The currently available carbapenems 
for clinical use are doripenem, ertapenem, imipenem, and meropenem.  
3.14.5.2 MECHANISM OF RESISTANCE: 
 The resistance towards carbapenem is classified into enzymatic and 
non-enzymatic. The non-enzymatic reasons for the resistance towards 
carbapenem are, 
3.14.5.2.1 Over- expression of efflux pumps: 
 The most commonly observed pump system in Pseudomonas 
aeruginosa is MexABOprM (Multidrug efflux system AB- Outer membrane 
protein M). It consists of the MexA, the MexB and the OprM exit portal. 
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The overproduction of the efflux pump is due to the upregulation or 
mutation in the mexR gene which results in the resistance to Meropenem. 
When the over-expression efflux pump coexists with the reduced outer 
membrane permeability then there develops resistance to other carbapenems 
also 25. 
3.14.5.2.2 Diminished outer membrane permeability: 
Carbapenems enter the P.aeruginosa through the outer membrane 
porin OprD. Due to the mutation in the OprD gene there will be loss of 
porins which results in the Imipenem resistance. The down regulation in the 
OprD outer membrane porin leads to reduced susceptibility to Meropenem 
but the β lactams are not affected. The loss of OprD porin or diminished 
expression is the frequent causes of the failure in the treatment with 
Imipenem
7
.  
In a study done by J.K. Lee et al in Korea concludes that mutation in 
OprD gene from P. aeruginosa isolates was linked with the down-regulation 
of OprD transcription and Imipenem resistance
26
. 
  Carbapenem resistant but beta-lactam susceptible strains are mainly 
due to the diminished expression of OprD. But these are not seen in the 
multidrug resistant strains. 
3.14.5.2.3 Enzymatic – Beta-lactamases: 
 β-lactamases are the enzymes with serine proteases at their active-
site. β-lactamases destroy the amide bond of a β-lactam in a two-step 
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reaction. The positively charged residue of the enzyme attracts the 
negatively charged carboxylate group of the β-lactam antibiotic and binds 
with the help of hydrogen bonding. The β-lactam is acylated.  A 
strategically positioned water molecule deacylates the β-lactam antibiotic 
and regenerates the enzyme β- lactamase7. 
3.14.5.2.3.1 Classification of β-lactamases: 
  β-lactamases are classified according to two properties, the functional 
and molecular level. 
3.14.5.2.3.1.1 Functional classification: 
Functional classification proposed by Bush-Jacoby in 1988 is widely 
accepted and it classifies the β-lactamases into four major functional groups. 
 Group 1 cephalosporinases,  
 Group 2 penicillinases,  
 Group 3 metallo-β-lactamase,  
 Group 4 is unclassified. 
In the functional classification, carbapenemases are found principally in 
groups 2f and 3. 
3.14.5.2.3.1.2 Molecular classification: 
 The structural classification by Ambler includes four molecular 
classes:  
A) The Extended Spectrum Beta-Lactamases (ESBL) that are 
inhibited by clavulanic acid,  
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B) The Metallo-Beta-Lactamases.  
C) The Cephalosporinases.  
D) The Oxacillinases.  
The enzymes in Classes A, C and D have serine in their active site. 
The MBLs bear zinc in their active site. The amide bond of the beta-lactam 
ring is cleaved by the serine enzymes to inactivate the antibiotic, while 
MBLs use one or two divalent Zn
2+
 cations to catalyze the same chemical 
reaction. 
The carbapenemases in P.aeruginosa belong to Ambler class B, 
commonly referred to as metalloenzymes. 
3.14.5.2.3.1.3 Bush Jacoby Classification: 
 They classified the beta lactamases into 4 groups (1-4) and 5 
subgroups (a-f) 
Group 1: involves cephalosporinases that resist to clavulanic acid, 
comparable with the class C in Ambler scheme. 
Group 2: consists of penicillinases and cephalosporinases that are inhibited 
by clavulanic acid, comparable with the class A and D in Ambler 
classification. The TEM and SHV were originally classified in this group. 
Due to the increase in the number of TEM and SHV derived beta 
lactamases, this group as divided into 2 subclasses, 2a and 2b. 
 Subgroup 2a: composed of penicillinases. 
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 Subgroup 2b: consists of broad spectrum beta lactamases which can 
inactivate penicillins and cephalosporins at the same rate. 
 There are sub-subgroups, 2be and 2br classified under the subgroup 
2b. 
 Sub-subgroup 2be: is consisted of Extended spectrum beta 
lactamases that can hydrolyse the third generation cephalosporins like 
cefotaxime, ceftazidime and cefpodoxime. It also hydrolyzes the 
monobactams (aztreonam). 
 Sub-subgroup 2br: this group contains the enzymes that are resistant 
to clavulanic acid and sulbactam. This is named „r‟ due to its reduced ability 
to bind to clavulanic acid and sulbactam. This group is called inhibitor-
resistant TEM derivative enzymes but is still sensitive to tazobactam. 
Subgroup c: this group was later separated from subgroup 2b which have 
the property to inactivate carbenicillin more efficiently than benzyl 
penicillin. 
Subgroup 2d: this group of enzymes is able to hydrolyze cloxacillin and 
carbenicillin more than the benzyl penicillin and also inhibited by clavulanic 
acid. 
Subgroup 2f: this group consists of serine based carbapenemases but is 
different from zinc based carbapenemases in group 3. 
Group 3: this group consists of zinc based carbapenemases or metallobeta 
lactamases comparable with the Ambler class B. This is the only group 
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which requires the metal ion zinc for their catalytic activity. These enzymes 
hydrolyze penicillins, cephalosporins and carbapenems. 
Group 4: is the group composed of penicillinases that resist to clavulanic 
acid and not comparable with any of the group in the Ambler class. 
3.15 METALLO-β-LACTAMASE: (MBL) 
The first metallo-β-lactamase isolated were chromosomal enzymes 
that were present in environmental and opportunistic bacteria. These 
chromosomal enzymes express serine β lactamase, inducible only after the 
exposure to β lactam antibiotics. The genes responsible for the chromosomal 
enzymes are not easily transferred. 
 There are some acquired or transferable families of these metallo 
enzymes which spread through plasmids or transposons between bacteria. 
The most common metallo β lactamase families include the VIM, IMP 
genes located in integrons. Transferable carbapenem resistance in a P. 
aeruginosa isolate was first discovered in Japan in 1990
27
.  
The important features of metallo β lactamase are listed below, 
 Class B metallo β lactamases use a Zn2+ cation for hydrolysis 
of the β-lactam ring. 
 They hydrolyse all β-lactam antibiotics like penicillins, 
cephalosporins and even carbapenems except monobactam. 
 They are susceptible to ion chelators such as ethylene diamene 
tetraacetic acid (EDTA) and thiol compounds. 
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 They are not inhibited by the β-lactamase inhibitor such as 
clavulanic acid. 
3.15.1 CHEMICAL NATURE OF MBLs
7
:  
 MBLs carry a set of amino acids with two zinc ions at their active 
site. The zinc ions have two water molecules which is essential for 
hydrolysis. The major zinc-binding site is histidine-X- histidine-X-aspartic 
acid (HXHXD). These two   zinc binding sites function separately with the 
primary zinc binding site assisted by the secondary site. This is common to 
all types of MBLs except the class B2 enzymes. The class B2 enzymes have 
only one zinc ion at their active site. 
 These MBL enzymes contain a αββα site with a central β and two 
helices on each side. The zinc ions are held in place by three histidines 
molecule and a water molecule. The water molecule plays a critical role in 
catalysis of the antibiotics. 
 The zinc in the active site positions the β-lactam bond to enable 
nucleophilic attack by zinc-bound water and hydroxides. These enzymes are 
resistant to the inhibitors such as clavulanic acid and sulbactum they will 
not hydrolyze aztreonam particularly well. 
3.15.2 CLASSIFICATION OF METALLO-β-LACTAMASES: 
3.15.2.1 Depending on the zinc requirement: 
 Metallo β lactamases can be clustered into three different 
subclasses (B1, B2, and B3) depending on their requirements for zinc. 
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B1 enzymes: They are fully active with one or two zinc ions.  These 
include IMP-1, VIM-2, and CcrA. 
B2 enzymes: These enzymes are inhibited by the addition of second 
zinc ion. The example is CphA. 
B3 enzymes: These enzymes require two zinc ions. Eg: L1 
3.15.2.2 Depending on the carbapenem hydrolyzing capacity: 
On the basis of carbapenem hydrolyzing capacity the class B enzymes 
are divided into three groups 
 3a: It has a broad spectrum activity. The examples include BCII, 
IMP-I, Ccr A, VIM, GIM, SPM-1. It has property of binding of two zinc 
atoms for optimal hydrolysis. Three molecules of histidine are present in the 
one binding site of the zinc and asparagine, cysteine and histidine are 
present in the second binding site of zinc in the enzyme. 
 3b: It has preferential activity towards carbapenem. The examples 
include Cph A, Sfh-1. It has two molecules of histidine and one molecule of 
asparagine in the first binding site of the zinc atom. The addition of second 
zinc atom is inhibitory to the catalytic activity of the enzyme. 
 3c: It has high specificity for hydrolyzing cephalosporins but has poor 
activity against carbapenem. It has three histidine molecules in the first 
binding site and two histidine and a asparagine molecule in the second 
binding site which will be helpful in the optimum hydrolysis of the 
antibiotics. 
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3.15.2.3 Depending on the location of the MBL gene: 
According to the location of MBL gene they are classified into two types, 
 Transferable MBLs 
 Chromosomally mediated MBLs 
3.15.2.3.1 Chromosomally Mediated MBLs: 
 Most of the metallo β lactamases are chromosomally encoded. Their 
expression can be constitutive or inducible. In B. cereus, Stenotrophomonas 
maltophilia, Aeromonas hydrophila, and Aeromonas jandaei the metallo β 
lactamases are inducible.  
Fortunately, these bacteria are generally opportunistic pathogens and 
are not frequently associated with serious nosocomial infections. But these 
bacteria show high level resistant to β lactams. As these MBL genes are 
chromosomally encoded, they are not easily transferred. 
3.15.2.3.2 TRANSFERABLE MBLs
28
: 
The Transferable MBLs are classified into five types according to the gene 
constituent, 
i. IMP ( “Imipenemases”) 
ii. VIM (“Verona integron-encoded metallo β lactamase”) 
iii. SPM (“Sao Paulo metallo β lactamase”) 
iv. GIM (“German imipenemase”) 
v. SIM (“Seoul imipenemase”). 
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 The Transferable MBLs are located in the integrons.  Integrons are 
the genetic elements of variable length that consists of three regions namely, 
5‟conserved region, 3‟ conserved region, and a variable region and has 59 
conserved integrase gene (int), an integration site for the gene cassette, attI 
(attachment) and mobile antibiotic resistance genes called cassettes 
respectively.  
By using a site-specific recombination system, integrons capture 
antibiotic resistance gene cassettes. There are about five distinct integron 
classes are associated with antibiotic resistance gene cassettes. Three major 
classes of integrons class1, class2 and class 3 have been described for gram-
negative bacteria.  
Integrons which have β lactamases are commonly present in  A. 
baumannii, P. aeruginosa, and other species of gram negative bacteria 
included in Ambler class A, B, and D β lactamases.  
The integrons which carry multiple resistance gene cassettes can be 
readily mobilized. Hence they are significant in the spread of antibiotic 
resistance. 
 Integrons are found to be an important source for the spread of bla 
gene. The bla gene types like IMP-1 to IMP-4, IMP-6 to IMP-8, IMP-12, 
VIM-1, VIM-2, and GIM-1 are also included in integron encoded β 
lactamases. 
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3.15.2.3.2.1 IMP type MBLs: 
 IMP (Imipenemase) was the first transferable MBL isolated from 
P.aeruginosa strain GN17203 in Japan during 1988. It has a high MIC for 
imipenem and also exhibited resistance to cephalosporins such as 
ceftazidime. These resistance alleles were set up on a mobile conjugative 
plasmid which can be easily transferred to other P.aeruginosa strains. These 
alleles were found in the class 1 integron. 
 The same identical gene isolated in Serratia marcescens Tn9106 from 
an UTI patient, three years later was found in class 3 integron. 
 To date there are up to 18 members in the IMP family listed on the β 
lactamases nomenclature.  
 Johann D. D. Pitout et al 2004, in his studies obtained about 2% of 
the IMP gene from 241 clinical strains of imipenem resistant P. aeruginosa 
from the centralized laboratory in the Calgary Health Region
29
. 
 In a study Fallah F, et al out of 83 imipenem resistant strains 48 were 
MBL producers. PCR and Sequencing methods proved that these 48 isolates 
were positive for blaIMP-1 genes, none of them were positive for blaVIM 
genes
30
. 
 Sepehriseresht S et al in his study reported that from the 483 isolates 
of carbapenam resistant and intermediate P.aeruginosa strains in burn 
patients from Iraq, ninety-four isolates had VIM and IPM genes in their 
PCR results.
31
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 A study by Dong et al. reported that among 146 strains of multi drug 
resistant Pseudomonas aeruginosa, 46 (31.5%) were positive for the MBL 
production and carried the blaIMP and blaVIM gene.
32
 
 Nam Hee Ryoo et al in his study stated that 31 Pseudomonas 
aeruginosa isolates were producing the MBL enzyme and 21 among them 
were positive for IMP gene and 10 were positive for VIM gene
33
. 
3.15.2.3.2.2 VIM type MBLs: (“Verona integron-encoded metallo β 
lactamase”) 
The VIM type of enzymes is the second main group of acquired 
MBLs. VIM-1 was first described in Verona in 1997, from a P. aeruginosa 
isolate.  It was found to be resistant to most of the β lactams and also the 
aztreonem.  The resistance to the aztreonam may be due to efflux 
mechanism and increased production of cephalosporinases. 
 In 1996, VIM-2 was isolated in France from a P. aeruginosa isolate. 
This isolate was resistant to most β lactams but they are susceptible to 
aztreonam. VIM-2 is identical with 90% amino acid of VIM-1.  The VIM 
family at present consists of 14 members and VIM-2 is the most-reported 
metallo β lactamase worldwide34. 
  M.J. Carvalho et al in a study, 27 clinical isolates of Pseudomonas 
aeruginosa were found to be resistant to Imipenem and the PCR detected 
the presence of blaIMP and blaVIM gene
35
. 
38 
 
 In a study on molecular characterization of carbapenem resistant 
strains by Masoumeh Doosti, et al with 70 nosocomial isolates, forty four 
were resistant to Imipenem and DNA sequencing revealed the VIM-2 
determinant
36
.  
 Fereshteh Shahcheraghi et al in their study stated that out of 610 
Pseudomonas aeruginosa isolates, 68 were found to be imipenem resistant 
with MIC ≥4 μg/ml. The PCR results for these 68 isolates showed only 16 
isolates harbored blaVIM gene. No other genes like IMP, SPM were 
detected in this study
37
.  
Mariana Castanheira et al (2009) in their study isolated 301 
P.aeruginosa collected from 10 Indian hospitals. The isolates producing 
VIM gene were detected in most of the participating hospitals and 5 bla 
VIM variants were detected
38
. 
 Horieh Saderi et al in a study reported that out of 100 Pseudomonas 
aeruginosa isolates in burn patients, 65% isolates were found to be 
imipenem resistant and 13 among these isolates when subjected to PCR 
results in detection of VIM 2 gene. MBL genes like IMP were not 
detectable
39
. 
 M. Shanthi Amudhan et al in her study concluded that the blaVIM 
gene was the most common MBL gene isolated. From a total of 179 
samples, 61carbapenem resistant Pseudomonas aeruginosa were isolated. 
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About 51.4% isolates were positive for the presence of blaVIM and blaIMP 
and concluded that the VIM gene was more prevalent
40
.  
3.15.2.3.2.3 SPM (Sao Paulo MBL): 
 This was isolated from a P. aeruginosa isolate in 1997 in Sao Paulo 
in Brazil. The strains were found to be resistant to all antibiotics against 
gram-negative bacteria except Polymixin E. This is more often related to 
IMP gene. 
 Alexandre R. Marra et al 2005, from Sau Paulo Brazil, reported that 
out of the 76 P. aeruginosa isolates, four(5.3%) of them showed MBL gene 
blaSPM-1 recovered from the blood stream infections and the other genes 
obtained were blaIMP [3.9%] and no blaVIM MBL gene was detected
41
. 
 Maria Renata Gomes Franco et al in their study reported that about 
30.4% of the carbapenem resistant P. aeruginosa isolates were MBL 
positive, with 81% positive for SPM-1 and 19% positive for VIM-2. They 
also concluded that SPM-1 (Sao Paulo) metallo-b-lactamase is the most 
prevalent MBL in Brazil
42
. 
3.15.2.3.2.4 GIM-1 (German imipenemase) 
26
: 
 In Germany, a newer β-lactamase named GIM-1 was isolated from 
five P. aeruginosa isolates in 2002. These isolates were susceptible only to 
polymyxin B. 
 GIM-1 has two zinc ions at its active site is the main feature of the 
MBL class B1 family. GIM-1 is similar to that of IMP-1. 
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3.15.2.3.2.5 SIM-1 (“Seoul imipenemase”) 
25
:   
The newer family of acquired metallo-β-lactamases was discovered 
from Korea. This SIM-1 enzyme has about 64 to 69% amino acid identity to 
the IMP family. SIM-1 metallo -β-lactamase is located within a class 1 
integron. 
 The SPM, GIM, and SIM metallo-β-lactamases have not spread 
beyond their countries of origin. But, VIM and IMP genes are detected 
worldwide. These two particular genes are currently spreading into the 
Enterobacteriaceae beyond the P. aeruginosa. 
In two different studies Bashir et al 
8
., 2011, Pitout et al 
29
., 2007 
concluded that MBL genes have spread from P.aeruginosa to 
Enterobacteriaceae in recent years. 
3.15.2.3.2.6 NDM-1(New Delhi Metallo β lactamase) 
Recently a newer type of carbapenemases, New Delhi metallo β 
lactamase-1(NDM-1) is making a spurt all over the world. It was first 
detected in Klebisella pneumonia isolate from a Swedish patient of Indian 
origin in 2008. The gene was found in an integron. NDM-1 mimics little 
with other MBLs mainly with VIM. It possess unique residues near the 
active site, NDM- 1 also has an extra insert between locations 162 and 166, 
which is not present in other MBLs. The molecular mass of NDM-1 is 28 
kD and is monomeric. It hydrolyzes all the beta lactams except aztreonam
43
. 
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Refath Farzana et al in Bangaladesh in their study reported that out of 31 
MBL positive isolates by PCR, 8 isolates were positive for NDM gene
44
. 
3.16 MULTIDRUG RESISTANT PSEUDOMONAS AERUGINOSA: 
(MDRPA) 
 The P. aeruginosa resistant to three or more antimicrobial classes are 
said to be multidrug resistant P. aeruginosa 
45, 46
.  The projected annual 
incidence of MDRPA infected patients have been increased from 2007 to 
2010
47
. The rates of multidrug resistance increased from 4 to 14% from the 
year 1993 to 2002, with decreasing susceptibility to most of the 
aminoglycosides, beta lactams and ciprofloxacin
45
.  
Elizabeth et al in their studies reported that the multidrug resistant P. 
aeruginosa isolates in the blood stream are about 10-17% from 2005 to 
2007
6
. 
3.17 PHENOTYPIC METHODS FOR MBL DETECTION: 
 Metallo beta lactamases (MBLs) produced by Pseudomnonas 
aeruginosa poses a serious problem due to their ability of transmission 
between the same as well as different bacterial species. Though there are no 
CLSI guidelines in the detection of MBL there are many different methods 
to detect MBLs which may be performed in the laboratory. 
3.17.1 Meropenem – EDTA combined disc test (CDT): 
 Test organisms in 0.5 Mc Farland turbidity standard is inoculated on 
to Mueller Hinton agar plate as for the routine disc diffusion procedure. 
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Meropenem discs are used as per the CLSI guidelines. Two 10 μg 
Meropenem discs (Himedia) are placed on the plate. To one of the discs, 10 
μL of 0.5 M EDTA solution is added. The plate is incubated aerobically at 
35°C for 16 to 18 hours. The zone of inhibition of the Meropenem and 
Meropenem-EDTA discs are compared. In the CDT, if the zone of 
inhibition of the Meropenem with the EDTA disc is ≥ 7 mm than the 
Meropenem disc alone, then it is considered as MBL positive. 
 Valenza G, et al in 2010, with 489 clinical isolates when investigated 
for MBL production from Germany university hospital suggested that the 
CDT is a valid alternative to the molecular investigation of MBL 
detection
48
. 
Deeba Bashir et al from Kashmir in 2008  in their study regarding 
detection of MBL in clinical isolates reported that out of 283 P. aeruginosa 
isolates 38 were resistant to imipenem and 33 were found to be MBL 
producers by CDT and all of them showed reduction in MIC with E test and 
agar dilution method. This study suggested that due to the cost constraints of 
the E test and laborious procedure of the agar dilution method, a simple 
screening test like the CDT can be used
8
. 
Vasanthi et al in their study reported that the CDT and DDST were 
the two phenotypic tests that can be used for the detection of the MBL 
production
49
. 
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A study by P Pandya et al 2011, on evaluation of phenotypic methods 
on MBL detection in gram negative bacilli reported that out of 450 P. 
aeruginosa isolates about 27 were positive for MBL production.  The 
production of MBL was highest in Pseudomonas (9.92%) than other gram 
negative bacilli.  The CDT detected 26 isolates (96.30%) and DDST 
detected 22 isolates (81.48%) as MBL producer and the author concluded 
that the CDT is the most sensitive method for detection of MBL production 
in gram negative bacilli and there is subjective variation in interpreting the 
result of DDST. The results were more obviously interpreted in CDT than 
DDST
50
.  
3.17.2 Meropenam-EDTA double disk synergy test (DDST): 
 The test strain is inoculated on to the Mueller Hinton agar plate. A  
Meropenem (10 μg) disc was placed 10 mm centre to centre from a blank 
disc containing 10 μL of 0.5 M EDTA (750 μg)51. The zone of inhibition in 
the area between Meropenem and the EDTA disc is enhanced in comparison 
with the zone of inhibition on the far side of the drug is interpreted as a 
positive.    
 Kumar SH, et al reported in their study that 26.9% of carbapenem-
resistant Pseudomonas aeruginosa and Acinetobacter species were detected 
as MBL by DDST and the author also stated that Meropenem was 
considered to be the best screening and confirmatory agent for detection of 
MBL and the gene more prevalent in that part was blaVIM 
52
. 
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In a study by Kalantar E, et al the DDST for the detection of MBL 
showed that out of the 100 P. aeruginosa isolates, 22 (22%) were positive 
for MBL 
15
.  
 Yousefi S, et al from Iran in his study stated that among 104 clinical 
isolates of Pseudomonas aeruginosa,39 (37.50%) were MBL positive by 
DDST
53
. 
Bogiel T, et al in his study reported that from 67 carbapenam resistant 
strains from intensive care units, about 72.9% of the isolates are positive for 
MBL by DDST.
54
  
Johann D.D Pitout et al., 2005 stated that the DDST has 100% 
sensitivity and 97% specificity in detecting MBL production in 
P.aeruginosa and suggested that it is better than the MBL E test
29
. 
3.17.3 MBL E-test: 
 The MBL E-Test strip contains a dual sided dilution range of 
Meropenam (MP) (0.125 to 8μg/mL) and Meropenem with EDTA (MPI) 
(0.032 to 2μg/mL) has been reported to be the most sensitive format for 
MBL detection. The E-test was done according to manufacturer's 
instructions. MIC ratio of MP (Meropenem)/MPI (Meropenem-EDTA) of 
>8 or deformation of ellipse or phantom zone is considered to be positive 
for MBL production. 
 Kaleem F, et al in a study reported that the MBL E test can be used to 
confirm the MBL
55
. A study by van der Bij et al reported that  the sensitivity 
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and the specificity for the E test was 100% and 95% respectively in the 
detection of MBL
56
. 
 Saha R et al in their study reported that out of 87 isolates of 
P.aeruginosa 31 isolates were resistant to carbapenem and 61% of these 31 
isolates, were MBL producers by CDT, while 48% were detected by E-test 
method
57
. 
3.18 INDIAN SCENARIO: 
  Various studies from India quoted the prevalence of MBL 
varying from 8-14% (Bashir et al
8
., 2011; Varaiya et al
58
., 2008; Hirakata et 
al
59
., 1998).  Ram Gopalakrishnan et al in his study on a retrospective 
review of surveillance over the period 2001-2008 reported the antimicrobial 
resistance patterns in Indian hospitals have a high prevalence that up to 40% 
of P. aeruginosa was resistant to carbapenems
60
. 
 Prashant Durwas Peshattiwar et al from Bijapur 2010, in his study 
reported that about 7.8% of P.aeruginosa was MBL producers
61
. 
 Deeba Bashir et al from Kashmir in his study stated that the 
prevalence of MBL producing P.aeruginosa were about 11.66%
8
.  Agrawal 
et al from Nagpur concluded that about 8.05 % of the P.aeruginosa 
produces the metallo beta lactamase enzyme
62
. In a study by Seema Bose et 
al from Maharashtra in their study reported that 15.71% were MBL 
producers
63
. 
46 
 
 There are some studies that showed higher prevalence rates in India. 
Vikas kumar et al revealed in his study from North India that 87.17% were 
metallo beta -lactamase producers 
64
. Noyal et al from Pondicherry reported 
50% of the resistant isolates were MBL producers
65
. The prevalence rate of 
MBL in P.aeruginosa isolates was 51.4% reported by Shanthi amudhan et 
al
40 
from Chennai. 
3.19 GLOBAL SCENARIO: 
 Various studies across the world have shown different rates of MBL 
production in P.aeruginosa isolates. The prevalence rate ranges from 43% - 
82% in countries like Bangaladesh(Nasrin et al
66
), Brazil(Pellegrino et al
67
., 
Magalhaes et al
68
.), Iran(H.Saderi et al
39
.), Italy(Lagatolla et al
69
) and 
Korea(K.Lee et al
70
). 
 Ting-ting Qu et al reported the lower prevalence rate in hospitals of 
China as 9.1%
71
. Yoshichika Arakawa et al in their study stated that 4.4% of 
the Pseudomonas aeruginosa were MBL producers with IMP gene in Japan. 
The author also quoted that similar type of MBLs was also prevalent in 
Italy, U.K and Singapore
72
. In Asia, blaIMP and blaVIM are prevalent
40 
as 
seen in the above studies and bla SPM were more prevalent in Brazil. 
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4. MATERIALS AND METHODS 
 
In the present study 100 Pseudomonas aeruginosa isolates obtained 
from various clinical specimens like pus, urine, burn, wound, sputum, 
pleural fluid and CSF from inpatients admitted to Tirunelveli medical 
college, Tirunelveli were included. The study period was from April 2013 to 
May 2014.These isolates were studied for detection of MBL production in 
Pseudomonas aeruginosa including their antibiogram.  
4.1 INCLUSION CRITERIA  
1. Specimens from patients admitted in wards were only included.  
2. All isolates of Pseudomonas aeruginosa confirmed by biochemical 
reactions 
3. Isolates showing resistance to Meropenem were only tested for 
production of metallo beta lactamase enzyme.  
4.2 EXCLUSION CRITERIA   
1. Specimens from outpatient department. 
4.3   METHODOLOGY  
4.3.1 Collection and Processing Of Various Samples:  
 A total of 100 non replicate isolates of Pseudomonas aeruginosa from 
clinical samples were taken in the study. All samples were collected under 
aseptic precautions by standard procedures and processed according to 
standard guidelines. Brain heart infusion broth was used for the blood 
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culture. The broth which showed turbidity was sub-cultured onto the 
MacConkey Agar and blood Agar media using sterile technique. 
 The urine specimens were centrifuged and inoculated on to the 
culture media. The wound swab and the other specimens such as pus, 
sputum were inoculated in the culture media and was also used for direct 
gram stain. The incubation was done at 37˚C for a period of 18-24 hours 
aerobically. 
 4.3.2 Ethical clearance  and Informed consent : 
 The ethical committee clearance was obtained from our institution 
and informed consent was obtained from all patients included in the study. 
 4.3.3 Proforma: 
 The proforma was filled with the details like name, age, sex, 
ward, clinical diagnosis, risk factors, undergone any surgery, duration of 
hospital stay and other parameters significant to the present study. 
4.3.4 Sample storage:  
The Pseudomonas aeruginosa isolates were sub-cultured on to 
nutrient agar slope and stored at 2 to 8˚C. The isolates were sub-cultured in 
every two weeks.   
4.3.5 CULTURE IDENTIFICATION OF PSEUDOMONAS 
AERUGINOSA: 
The Pseudomonas aeruginosa isolates were identified by, 
morphology on Gram stained smear and morphology of colonies on solid 
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media like Nutrient agar, MacConkey agar and Blood agar, the 
characteristic odour in culture plates, oxidase test, motility, biochemical 
reactions and growth at 42˚C. 
4.3.5.1 GRAM STAINING:  
Pink colored bacilli arranged in discrete pattern were identified as 
Gram negative bacilli. 
4.3.5.2 COLONY MORPHOLOGY:  
Nutrient agar:  smooth, large, green pigmented, translucent colonies with 
earthy odour. 
MacConkey agar: Colourless, non-Lactose fermenting colonies with 
spreading edges. 
Blood agar: Beta hemolytic, greyish white colonies with metallic sheen. 
4.3.5.3 MOTILITY (HANGING DROP METHOD):  
 The active motility, characteristic of P.aeruginosa was seen. 
4.3.5.4 BIOCHEMICAL REACTIONS: 
 The P.aeruginosa gave the following biochemical reactions, 
 Positive catalase test 
 Positive oxidase test 
 Oxidative pattern in Hugh – Leifson Oxidation – Fermentation test 
 Nitrate reduction to nitrite 
 Indole not produced 
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 Citrate utilized 
 Urea not hydrolyzed  
 Alkaline / Alkaline with no gas in Triple sugar iron agar 
 Methyl red negative 
 Voges – Proskaeur negative 
4.3.6 ANTIBIOTIC SUSCEPTIBILITY TESTING: 
 According to the CLSI guidelines the antibiotic susceptibility testing 
was done in the entire Pseudomonas aeruginosa isolates by Kirby Bauer 
disc diffusion method. 
4.3.6.1 Kirby-Bauer’s disc diffusion method: 
       About 3-5 colonies of the test organism were inoculated in 2 ml of 
peptone water and incubated for 2-4 hrs at 37˚C. Using Wickham‟s chart the 
turbidity of the inoculum was adjusted to 0.5 McFarland standards (1.5x10
8
 
CFU/ ml). A sterile cotton swab was soaked in the inoculum and a lawn 
culture was made on to the Muller-Hinton agar (MHA). By rotating the 
swab against the inner side of the test tube, excess broth was expressed. The 
panel of antibiotic discs was applied and incubated at 37˚C for 18-24 hours. 
The zone size was recorded and interpreted as per the CLSI guidelines 2013.  
The three interpretive categories are described as follows. 
Susceptible: 
 This indicates that the recommended antibiotic in appropriate dose for 
recommended period is the appropriate agent for treating the infection. 
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Intermediate: 
 This indicates that the tested organism may be inhibited by possible 
concentrations of certain drugs if higher concentrations of the drug can be 
used safely or if the infection includes a body site where that drug is 
physiologically concentrated (e.g., the urinary tract). 
Resistant: 
 The antibiotic tested may not be an appropriate choice for the 
infection against the tested organisms either they are not inhibited by the 
concentration of the drug normally achievable with the recommended dose 
or because the test result vastly correlates with a resistance mechanism. 
 In this study the susceptibility of the organism was tested against 
following antimicrobials from Hi-media laboratories Ltd, Mumbai. 
Table:1 Interpretation of Antibiotic susceptibility testing 
Antibiotic Concentration 
in μg  
Sensitive Intermediate  Resistant 
Ceftriaxone 30 >23 20-22 <19 
Cefotaxime  30  >26 23-25  <22  
Ceftazidime  30  >18  15-17  <14  
Gentamicin  10  >15  13-14 <12  
Amikacin  30  >17  15-16  <14  
 Ciprofloxacin  5  >21  16-20  <15  
Ofloxacin 5 >17 14-16 <13 
Meropenem 10 >19 16-18 <15 
Pip – Tazo 100 >21 15-20 <14 
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4.3.7 MBL detection by phenotypic methods: 
4.3.7.1 Initial screening with Meropenem by disc diffusion method: 
All the isolates of Pseudomonas aeruginosa are tested for the 
susceptibility for Meropenam by disc diffusion method as per the CLSI 
guidelines. 
About 3-5 colonies from the 24 hour young culture is inoculated in 
the peptone water and incubated for 2-4 hours. 0.5 Mc Farland standards 
suspension was prepared by adjusting the turbidity and checked by placing 
the tube side by side against a white card containing several horizontal black 
lines. Using a sterile cotton swab the inoculum is inoculated on to the 
Muller Hinton agar by streaking evenly over the surface of the agar in three 
directions with the plate rotated approximately 60° for even distribution. 
The plate was dried for 3-10 minutes before applying the Meropenem disc. 
The sterile needle was used to apply the disc. The disc was placed 15mm 
from the edge of the plate. The plate was incubated at a temperature of 37˚C 
for 16-18 hours.  
According to the CLSI guidelines the zone of inhibition was 
measured and interpreted. For Meropenem disc, zone size of ≥ 19mm was 
taken as sensitive while zone size of ≤ 15mm was taken as resistant. 
4.3.7.2 Detection of MBL: 
 The isolates which were found to be resistant to Meropenem 
were selected. These strains are subjected to various phenotypic methods 
53 
 
like combined disc test (CDT), double disc synergy test (DDST) and MBL 
E Test using Meropenem and EDTA to detect MBL production. They are 
confirmed genotypically by RT-PCR. For the negative control, ATCC 
27853 Pseudomonas aeruginosa was used. 
4.3.7.2.1 Combined Disc Test (CDT): 
Preparation of EDTA solution:  
 To prepare 0.5 M EDTA solution, 18.61g of disodium EDTA.2H2O was 
dissolved in 100 ml of distilled water. By using sodium hydroxide (NaOH) 
the pH was adjusted to 8.0. The solution was autoclaved. Every time for the 
procedure, 10 µl of 0.5 M EDTA solution was used. 
CDT procedure: 
As per the CLSI guidelines, the 24 hr young culture isolate of the test 
strain is inoculated on to the Muller Hinton agar plate. Two Meropenem 
discs 10 µg were placed on the dried agar plate. To one of the disc 10μl (750 
μg) of 0.5 M EDTA solution was added. The plate was incubated at 37˚C 
aerobically for 16-18 hours. The zone of inhibition was measured for the 
Meropenem and the Meropenem EDTA combined disc. The increase in the 
diameter of the zone by more than or equal to 7mm (≥7mm) for the 
Meropenem EDTA combined disc was considered MBL positive when 
compared to Meropenem alone. 
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4.3.7.2.2 Meropenem-EDTA Double Disc Synergy Test (DDST): 
The test strain was inoculated as lawn culture on to the Muller Hinton 
agar plate as per the CLSI guidelines. The Meropenem (10 μg) disc was 
placed 10 mm apart from the sterile blank disc. The sterile blank disc was 
added with 10 µl of EDTA and incubated at 37˚C for 16-18 hours. The 
enhancement of the zone of inhibition towards EDTA disc was considered 
positive for MBL production of the test strain. 
4.3.7.2.3 MBL E Test: 
MBL E test strip is a unique strip for the phenotypic detection of 
MBL is coated with mixture of Meropenem + EDTA and Meropenem in a 
concentration gradient manner. The strip is made of porous material and the 
antibiotics are distributed evenly on either side of the strip. It was used to 
determine the minimum inhibitory concentrations of the drug for the test 
strain. E test MBL strip has a double sided antibiotic concentration in a 
range of Meropenem (MP) 0.125 to 8 µg/ml and Meropenem + EDTA 
(MPI) 0.032 to 2 µg/ml with a fixed concentration of EDTA. 
Procedure: 
 The inoculum was prepared with 4-5 colonies from 24 hr young 
culture and inoculated as a lawn culture on to the Muller Hinton agar after 
adjusting the turbidity to 0.5 Mc Farland standards. The MBL E test strip 
container was taken from the freezer and kept at room temperature for 15 
minutes before opening .The strip was then taken with a sterile forceps or E 
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test applicator and applied to the dried agar surface with the MIC scale 
facing upwards. The plate was incubated aerobically for 16-18 hrs at 37
0
C.  
Interpretation: 
 The plate was read after the determined time of incubation. The MIC 
of the isolate was read where the zone of inhibition intersects the strip. The 
MIC for MP/MPI ≥ 8 or deformation of ellipse or phantom zone was 
considered positive for MBL production. 
4.3.7.2.4 MBL detection by PCR: 
The Meropenem resistant Pseudomonas aeruginosa isolates were 
further tested for blaIMP and blaVIM gene by Real-Time PCR. The PCR 
kit was procured from Helini Biomolecules, Chennai, India. According to 
the manufacturer‟s instructions, the procedure was performed. 
Requirements: 
 Micro Pipettes variable volume 0.5-10 µl, 10-100 µl, and 100-1000 µl 
  Sterile tips. 
 Vortex mixer 
 Water bath 
 13,000 rpm Centrifuge (Refrigerated) with rotor for 1.5ml reaction 
tubes 
 1.5ml/2ml centrifuge tubes 
 Thermo cycler (Biorad CFX 96) 
 Computer for data storage 
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DNA Extraction: 
The DNA extraction procedure yields purified DNA of more than 
30kb in size obtained after the lysis of the cell. This kit utilizes the silica 
based membrane technology in the form of a spin column. The isolated 
DNA can be used directly for the PCR amplification. 
Components of extraction 
 Phosphate buffered saline 
 Lysozyme 
 Digestion buffer 
 Binding buffer 
  Proteinase K 
 Internal control template 
 Isopropanol 
 70% Ethanol 
 Elution buffer 
Storage and stability: 
 The bacterial genomic DNA extraction kit was stored at room 
temperature. 
 The proteinase K and Lysozyme were stored at -20 
0
 C. 
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Bacterial pellet preparation:  
 About 4-6 colonies of the test strains were inoculated in peptone 
water and incubated at 37
0
C overnight. 1-1.5 ml of bacterial culture was 
transferred into the sterile 2ml centrifuge tube. The tube was centrifuged at 
8000rpm for 5 minutes at room temperature. The supernatant was discarded 
and the pellet was used for the DNA extraction. 
Principle: 
 The cells are lysed with the enzyme Proteinase K and the nucleases 
are inactivated by chaotropic salt. The nucleic acids are bound to special 
silica fibres in the spin column tube. The cellular components contaminating 
the bound nucleic acid is removed in a series of rapid “wash and spin” steps. 
The elution releases the nucleic acids from the silica fibre. 
DNA extraction procedure: 
1. The bacterial pellet was suspended in 200 µl phosphate buffer saline 
and the suspension is vortexed briefly. 
2. 180 µl of digestion buffer and 20 µl of lysozyme were added and 
vortexed for 10 seconds. 
3. The mixture is incubated for 15 minutes at 370C. 
4. 200 µl of binding buffer, 20 µl of proteinase K and 5 µl of internal 
control template was added and mixed well by pulse vortex. It was 
incubated in a water bath at 56
0
C for 15 min. 
5. 300 µl of Isopropanol is added and mixed well. 
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6. The entire sample was pipetted into the spin column. At 12,000rpm it 
was centrifuged for 1 minute. The flow through was discarded. The 
spin column was placed into the collection tube. 
7. 500 µl of 70% ethanol is added to the spin column. At 12,000rpm it 
was centrifuged for 1 minute. The flow through was discarded. The 
spin column was placed into the collection tube. This step was done 
twice. 
8. The empty spin column with the collection tube was centrifuged at 
12,000rpm for 2 minutes to avoid residual ethanol. 
9. The collection tube is discarded and the spin column was placed in to 
a fresh micro centrifuge tube. 
10. 75 µl of the pre-warmed (warmed at 560C) Elution buffer was added 
to the centre of the spin column and incubated for 2 minutes at room 
temperature. It was centrifuged for 1 minute at 13,000rpm. 
11. The spin column was discarded and eluted DNA was taken for the 
PCR procedure.  
PCR Amplification: 
 bla IMP and blaVIM primer & probe mix: 
The blaIMP and blaVIM primer & probe mix consists of TaqMan 
probe which is florescent labeled with FAM, forward primer and reverse 
primer. 
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For VIM gene: 
Forward primer: 
CGCGGAGATTGAGAAGCAAA 
Reverse primer: 
AGCCGCCCGAAGGACATC 
Probe sequence: 
TTGGACTTCCTGTAACGCGTGCA 
For IMP gene: 
Forward Primer:  
GGGCGTTGTTCCTAAACATGG 
Reverse Primer:  
CACGCTCCACAAACCAAGTG 
Probe:  
TGGTGGTTCTTGTAAATGCTGAGGC 
Internal Control primer & probe Mix             
The internal control primer & probe mix consists of TaqMan probe 
which is florescent labeled with HEX, forward primer and reverse primer. 
The internal control is included to make sure that PCR inhibitors removed 
during the DNA extraction procedure and the performance of PCR mix 
ingredients are good. The internal control if amplified shows that PCR 
inhibitors are not present in the sample and the nucleic acid purification is 
optimum. It helps to rule out false negative results.  
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Positive control: 
 blaVIM positive template is used as positive control. A positive result 
indicates that the primers and probes worked correctly in that particular 
experiment. 
Negative control: 
 Nuclease free water as used as a negative control. A negative result 
indicates that there is no contamination in the reagents. 
Materials required: 
 Real time PCR machine with FAM/JOE channel 
 0.2ml PCR tubes/8well strips 
 Micropipette and tips  
PCR detection mix:  
The blaIMP and blaVIM reaction mix for the samples consisted of 
probe PCR master mix 10µl, bla IMP primer probe mix 10µl, blaVIM and 
internal control primer probe mix 10µl, purified DNA sample 5µl and a total 
volume of 25µl.  
For positive control mix, 5µl of positive control template was added 
instead of sample DNA and for negative control mix, 5µl of nuclease free 
water was added instead of sample DNA.  
The negative control is added first followed by samples and finally 
positive control was added to prevent cross contamination. 
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The PCR detection mix was centrifuged after adding all the 
ingredients and they were placed in the thermo cycler where the PCR 
reaction was allowed to occur. 
Table:2. blaIMP reaction mix for samples 
S.No Components Volume 
1. Probe PCR Master Mix 10µl 
2. bla IMP Primer Probe Mix 10µl 
3. Purified DNA sample 5µl 
4. Total reaction volume 25µl 
 
Table:3.  blaVIM reaction mix for samples 
S.No Components Volume 
1. Probe PCR Master Mix 10µl 
2. blaVIM/IC Primer Probe Mix 10µl 
3. Purified DNA sample 5µl 
4. Total reaction volume 25µl 
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PCR amplification steps: 
Initial Denaturation: 
 This is the first step in the amplification procedure. The thermocycler 
raises the temperature to 95˚C for five minutes for Taq enzyme activation. 
Denaturation: 
 The temperature is elevated to 95˚C for 20 seconds. The double 
stranded template DNA gets separated into two complementary strands. 
Annealing: 
When the temperature is decreased to 55˚C for 20 seconds the 
complementary binding of the two specific oligonucleotide primers to the 
DNA template take place. 
Extension: 
The DNA polymerase extends the primers when the temperature is 
increased to 72˚C for 20 seconds. The template DNA is synthesised using 
deoxynucleotides (dNTPs) in the reaction mixture. Two single stranded 
DNA templates and newly synthesized complementary DNA strands attach                                      
together to form new double stranded DNA copies. Every copy of newly 
formed DNA may function as a template for further amplification. The 
products will be amplified in an exponential manner in each cycle. At the 
end of 40 cycles, the final PCR products will have 2n copies of template 
DNA.  Data analysis was made at the end of extension and the computer 
produces the cross threshold (Ct) value by calculating the fluorescence 
emitted at the end of each cycle.  
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Table:4. Amplification profile for blaIMP and blaVIM gene: 
` Step Time Temp 
Taq enzyme activation 5min 95
0
 C 
 
40cycles 
Denaturation 20sec 95
0
 C 
Annealing/ Data collection 20sec 55
0
 C 
Extension 20sec 72
0
 C 
 
VIM/IMP = FAM channel 
Internal control = HEX channel 
Interpretation of the results: 
Negative control: 
 The negative control reactions should not exhibit fluorescence growth 
curves that cross the threshold line. 
Positive control: 
 Positive control reactions should produce positive results before 40 
cycles. 
Test sample positive: 
 When all the controls fulfill the quantified requirements, a test sample 
is measured positive. Any samples which exhibit fluorescence that cross the 
threshold line at or after 38 cycles should be retested. 
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Test sample negative: 
 When all controls fulfill the quantified requirements, a test sample is 
measured negative. 
Internal control interpretation: 
 According to the protocols (assuming 100% extraction efficiency) the 
CT value is expected within 24-31 for the internal control. This may differ 
depending on the extraction efficiency, the quantity of elute added to the 
PCR reaction and the settings of machine. If the amplifying sample had high 
genome copy number then the internal control may not produce an 
amplification plot. This can be interpreted as positive result rather 
invalidates it. 
Table:5. Interpretation of results 
Test 
Sample 
Negative 
control 
Internal 
control 
Positive 
control 
Interpretation 
Positive Negative Positive Positive Positive 
Negative Negative Positive Positive Negative 
Negative Negative Negative Negative Repeat 
Positive Positive Positive Positive Repeat 
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5. RESULTS 
 
 5.1 Study Description: 
The study was conducted at the Department of Microbiology, 
Tirunelveli Medical College, over a period of one year from April 2013 to 
May 2014. A total of 100 Pseudomonas aeruginosa isolates from various 
clinical samples were included in the study. These isolates were subjected 
for Meropenem resistance by disc diffusion test and the resistant isolates 
were tested for MBL with phenotypic tests like CDT (Combined disc test), 
DDST (Double disc synergy test and MBL E test. They were also tested for 
the presence of genes like blaIMP and blaVIM by Real-Time PCR. The 
sensitivity patterns to the antibiotics for the isolates and the other risk 
factors were analysed. 
 
5.2 Statistical Analysis:  
Data regarding the subjects were defined in terms of percentages. The 
statistical measures were completed with the help of the statistical software 
IBM SPSS statistics 20. The p values < 0.05 was considered as significant 
(p <0.05) in Chi square and Mc Nemer test. 
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5.3 Analysis by age and gender:                           
    Table:6     Age – Sex distribution of the Study group 
Age (years) 
Male Female Total 
No % No % No % 
≤ 10 1 1.3 1 3.7 2 2 
11– 20 4 5.5 2 7.4 6 6 
21– 30 7 9.6 5 18.5 12 12 
31 – 40 8 11 8 29.6 16 16 
 41 – 50 11 15 2 7.4 13 13 
 51 – 60 21 28.7 2 7.4 23 23 
61 – 70 16 22.9 6 22.2 22 22 
≥70 5 6.8 1 3.7 6 6 
Total 73 73 27 27 100 100 
  
Out of 100 isolates, 86 isolates were between the age group of 21 and 
70 years. Among them 63 were males and 23 were females. The mean age 
of male was 50.75 years and that of female was 41.59 years. (Table: 6; 
Figure.1)   
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5.4 Distribution of Pseudomonas aeruginosa in clinical isolates: 
 The specimen wise distribution of Pseudomonas aeruginosa was 
analysed and about 72 isolates were from pus samples. 19 and 4 samples 
were from sputum and vaginal swab respectively. Two isolates were from 
urine samples and only one isolate was obtained from blood. Two isolates 
were from other body fluids (CSF and pleural fluid). Fig: 2. 
 
Table:7 Distribution of Pseudomonas aeruginosa in clinical isolates: 
S.No Specimen Number Percentage (%) 
1 Pus 72 72 
2 Sputum 19 19 
3 Vaginal Swab 4 4 
4 Urine 2 2 
5 Blood 1 1 
6 Other Body Fluids 2 2 
                  Other body fluids: CSF, Pleural fluid. 
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5.5 Resistance patterns of Pseudomonas aeruginosa to antibiotics: 
Table: 8 Resistance patterns to Antibiotics 
Antibiotic discs No .of resistant 
Isolates 
Percentage 
(%) 
Gentamicin 
(GEN) 10 µg 
69 69 
Amikacin 
(AK)30 µg 
42 42 
Ciprofloxacin 
(CIP) 5 µg 
71 71 
Ofloxacin 
(OF) 5 µg 
52 52 
Ceftazidime 
(CAZ)30 µg 
26 26 
Ceftriaxone 
(CTR) 30 µg 
90 90 
Cefotaxime 
(CTX) 30 µg 
93 93 
Piperacillin 100 µg 42 42 
Meropenem 
(MRP) 10 µg 
21 21 
 
The above table shows the resistance pattern of the various antibiotics 
to the Pseudomonas aeruginosa. 42% of the isolates show the resistant to 
Piperacillin. The resistant to the Ceftriaxone and cefotaxime is very high 
and it is more than 90%. The aminoglycosides like Gentamicin and 
Amikacin show resistance of 69% and 42% respectively. The Meropenem 
and Ceftazidime show about 21 and 26 percentages respectively. Among the 
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100 isolates, 21 were Meropenem resistant Pseudomonas aeruginosa 
(MRPA n=21) and remaining 79 were Meropenem sensitive Pseudomonas 
aeruginosa (MSPA) 
 
Resistance patterns of Pseudomonas aeruginosa to antibiotics 
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5.6 Screening test for MBL detection: 
Table: 9 Meropenem Resistance in Pseudomonas aeruginosa 
isolates by Disc Diffusion test: 
Total No of Pseudomonas 
aeruginosa isolates 
Meropenem Resistant 
Pseudomonas aeruginosa             
(MRPA) 
Meropenem 
Sensitive 
Pseudomonas 
aeruginosa (MSPA) 
 
                100 
 
                 21 
 
                   79 
  
The above table shows the results of initial screening test in the 
detection of MBL determined by disc diffusion test using Meropenem 
(10µg). The zone of inhibition<15mm is taken as resistant. Among the 
entire P.aeruginosa isolates 21 isolates showed resistance to Meropenem. 
 
MRPA 
21% 
MSPA 
79% 
Fig: 4 Meropenem Resistance in 
Pseudomonas aeruginosa isolates  
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5.7 Sex-wise distribution of MRPA: 
 
Table: 10 Sex-wise distribution of MRPA 
Gender MRPA Percentage MSPA Percentage Total  
Male  14 19.2 59 80.8 73 
Female 7 25.9 20 74.1 27 
 
 The above table describes the gender distribution in MRPA isolates. 
Among the 21 MRPA isolates, 14 were males and 7 were females. In case 
of MSPA about 59 isolates were from males and 20 from females. The p 
value with the chi square test is 0.462 which is not statistically significant. 
(Table:10, Fig:5) 
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Sex Distribution of MRPA 
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5.8. Distribution of MRPA isolates from various wards: 
    Table: 11 Distribution of MRPA isolates from wards 
Ward 
MRPA MSPA 
No % No % 
Surgery 8 38.1 50 63.3 
Sick Neonatal ward 1 4.8 0 0 
Orthopaedics 4 19.0 5 6.3 
O&G 3 14.3 4 5.1 
Burns 0 0 2 2.5 
ENT 2 9.5 1 1.3 
Urology 1 4.8 1 1.3 
Medicine 2 9.5 16 20.3 
Total 21 100 79 100 
 
The above table shows the distribution of MRPA samples from 
various departments of the hospital. Majority of the MRPA isolates were 
from Surgery department i.e 8 (38.1%) from the total of the 58 isolates. 
About 4 MRPA isolates (19%) were from Orthopaedics department which 
contributes the second major cases. Three isolates were from O&G 
department and 2 isolates were from medicine and ENT department 
respectively. (Table:11, Fig:6) 
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5.9. Categorization of MRPA and MSPA on infection basis: 
        Table: 12 Categorization of MRPA and MSPA on infection basis: 
Infections 
MRPA MSPA 
No % No % 
Wound infections  8 38.1 33 41.8 
Abscess  1 4.8 6 7.6 
Ear discharge 2 9.5 1 1.3 
Vaginitis  3 14.3 1 1.3 
Respiratory tract infections 2 9.5 18 22.8 
Diabetic foot 3 14.3 11 14.0 
Urinary tract infections  1 4.8 1 1.3 
Burns 0 0 6 7.6 
Others  1 4.8 2 2.6 
Total 21 100 79 100 
 
Table 12 shows the categorization of Pseudomonas aeruginosa on 
infection basis. On analyzing various infections associated with 
Pseudomonas aeruginosa, 38.1% of MRPA isolates were associated with 
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wound infections, 14.3% of MRPA isolates were associated with vaginal 
infections and diabetic foot, 9.5% constitutes respiratory infections and ear 
infections. (Fig.7) 
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5.10. Analysis of various phenotypic methods for the detection of the 
MBL production: 
 The 21 isolates which showed resistance to Meropenem were 
evaluated for the production of MBL by various phenotypic methods like 
CDT, DDST and MBL E test. Among them, 14 isolates showed MBL 
production by CDT and 12 were positive with the DDST. The MBL E test 
detected about 10 isolates which were considered positive for MBL 
production. (Table:13 and Fig:8)   
  
            Table: 13 Detection of MBL by various phenotypic methods  
                 MRPA  n = 21 
Method 
MBL producer 
No % 
CDT 14 66.7 
DDST 12 57.1 
E Test 10 47.6 
 
 
 
 
79 
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Fig: 8 Detection of MBL by Phenotypic methods 
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80 
 
5.11. Prevalence of blaVIM and blaIMP gene in the Meropenem 
resistant isolates: 
 
Table: 14.  Detection of MBL by REAL TIME PCR. 
Gene amplified No of isolates Percentage % 
VIM 10 47.6 
IMP 0 0 
Not amplified 11 52.3 
Total 21 100 
 
Among the 21 Meropenem resistant isolates, ten (47.6 %) were positive 
for the presence of blaVIM gene by Real Time-PCR. blaIMP gene was not 
detected in any of the Meropenem resistant isolates. (Table 14, Fig:9 ).      
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5.12. Comparison of CDT and PCR for detection of MBL: 
Table: 15. Comparison of CDT and PCR for detection of MBL 
CDT PCR 
Positive Negative Total 
Positive 9 5 14 
Negative 1 6 7 
Total 10 11 21 
 
Among the 21 MRPA isolates, 14 isolates gave positive result with 
the CDT. The PCR detected the presence of MBL gene in 10 isolates. About 
9 CDT positive isolates and one CDT negative isolate were PCR positive.  
The sensitivity, specificity, positive predictive value and negative 
predictive value of CDT in the detection of MBL were 90%, 55%, 64.2% 
and 85.7% respectively. (Table: 15). The kappa value denoting the measure 
of agreement is low (0.438). 
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5.13. Comparison of DDST and PCR for detection of MBL: 
Table: 16. Comparison of DDST and PCR for detection of MBL: 
 
DDST 
PCR 
Positive Negative Total 
Positive 9 3 12 
Negative 1 8 9 
Total 10 11 21 
  
The DDST detected 12 among 21 MRPA isolates as MBL producer 
and the PCR detected the MBL gene in 10 MRPA isolates. Among 9 
isolates that were negative with the DDST, one isolate was PCR positive 
and the remaining 8 isolates were also negative in PCR. 
The sensitivity, specificity, positive predictive value and negative 
predictive value of CDT for detecting MBL were 90%, 72%, 90% and 61% 
respectively. (Table:16). The kappa value denoting the measure of 
agreement is moderate (0.622). 
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5.14. Comparison of MBL E test and PCR for detection of MBL: 
Table: 17.  Comparison of MBL E test and PCR for detection of MBL 
 
MBL E Test 
PCR 
Positive Negative Total 
Positive 9 1 10 
Negative 1 10 11 
Total 10 11 21 
 
Among 21 MRPA isolates, 10 isolates were positive with the E test. 
The 9 isolates with E test positive and one isolate with E test negative was 
PCR positive.  
The sensitivity, specificity, positive predictive value and negative 
predictive value of MBL E test were 90%, 90%, 90% and 90% respectively. 
(Table: 17). The kappa value denoting the measure of agreement is High 
(0.809). 
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5.15. Analysis of Risk Factors: 
5.15.1. Duration of hospital stay:              
About 81% of the MRPA isolates were obtained from the patients 
with more than 2 weeks of hospital stay. Only 20% of the MSPA isolates 
were from the patients with >2 weeks of hospital stay. The association of 
MRPA isolates with the duration of hospital stay was statistically 
significant. P < 0.05(Table.18 & fig.10) 
Table: 18. MRPA isolates by duration of hospital stay 
 
 
≤2 weeks >2 weeks
19.04 
80.96 79.74 
20.26 
Fig: 10.   Duration of Hospital 
stay 
MRPA MSPA
Duration in 
days 
MRPA MSPA 
No % No % 
≤2 weeks 4 19.04 63 79.74 
>2 weeks 17 80.96 16 20.26 
Total 21 100 79 100 
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5.15.2. Exposure to antibiotics: 
Table: 19 Antibiotic Exposure in patients with MRPA and MSPA 
Antibiotics MRPA 
n = 21 
MSPA 
n = 79 
Total Significance  
p<0.05 
Cephalosporins 8 (38.1%) 61 (77.2%) 69 Significant 
Aminoglycosides 3 (14.3%) 21 (26.6%) 24 Non -Significant 
Fluoroquinolones 1 (4.8%) 10 (12.7%) 11 Non -Significant 
BL+BLI 2(9.5%) 5 (6.3%) 7 Non -Significant 
Carbapenem 3 (14.3%) 2 (2.5%) 5 Non -Significant 
 
 There was statistically significant difference in exposure to 
cephalosporins among MRPA and MSPA isolates (P<0.05). There is no 
significance in the administration of other mentioned antibiotics with the 
corresponding MSPA and MRPA isolates.(Fig: 11)  
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 5.16. Resistance pattern to antibiotics in MRPA and MSPA isolates:              
Table: 20.  Resistance pattern to antibiotics in MRPA and MSPA 
isolates 
Antibiotics MRPA 
n = 21 
MSPA 
n = 79 
Total Significance 
p<0.05 
Amikacin 13 (61.9%) 29 (36.7%) 42 Significant 
Gentamicin 13 (61.9%) 56 (70.9%) 69 Non -Significant 
Ciprofloxacin 13 (61.9%) 58 (86.1%) 52 Significant 
Ofloxacin 40 (50.6%) 39 (49.4%) 45 Non -Significant 
Ceftazidime 21 (100%) 5 (6.3%) 26 Significant 
Ceftriaxone 21 (100%) 69 (87.3%) 90 Non -Significant 
Cefotaxime 21 (100%) 72 (81.1%) 79 Non -Significant 
 
 All the MRPA isolates were found to be resistant to cephalosporins. 
61.9% of the MRPA isolates were resistant to Amikacin,Gentamicin and 
Ciprofloxacin. The resistance to Amikacin,Ciprofloxacin and Ceftazidime 
were statistically significant. P<0.05. (Table:20, Fig: 12) 
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6. DISCUSSION 
 
Pseudomonas aeruginosa is the leading cause for the hospital 
acquired infections. Pseudomonas aeruginosa exhibits intrinsic resistance to 
various antimicrobials. It also shows acquired resistance to anti 
pseudomonal beta lactams such as piperacillin, cephalosporins and 
carbapenems. The rise in the resistance to the last resort drug carbapenem 
has become a major challenge in treating the P.aeruginosa infections. 
Several mechanisms are responsible for the acquired resistance to the β 
lactam antibiotics in P.aeruginosa which includes the production of β 
lactamases, up regulation of the efflux pump systems and decreased outer 
membrane permeability. With respect to β lactamases, the metallo beta 
lactamases are the emerging resistance mechanism in P.aeruginosa.  
The present study was aimed to identify the prevalence of MBL 
producing Pseudomonas aeruginosa isolated from various specimens in the 
Department of Microbiology, Tirunelveli medical college.  
6.1. Age – Sex wise distribution of the Study group: 
The present study showed that the P.aeruginosa was isolated more in 
the age group of 41-70 years (58%). A similar observation was noted by 
Bashir et al from Kashmir during 2007-2008
8
 and Viren A Javiya et al 
showed 60.7% of Pseudomonas aeruginosa were isolated in age group of 
41-70 years at a tertiary care hospital, Gujarat during 2006
73
.  
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In the present study P.aeruginosa was isolated more commonly in 
males (73%) when compared to females (27%) with a male: female ratio of 
2.7:1. A similar observation was made by Prashanth durwas et al in Bijapur, 
during 2008-2010 that Pseudomonas aeruginosa isolated was more in males 
with the male to female ratio as 1.8: 1
61
. Unlike the present study, Bashir et 
al in his study showed that the male: female ratio was 1.2: 1 where the male: 
female ratio was relatively equal
8
. 
6.2. Distribution of Pseudomonas aeruginosa in wards: 
The rate of isolation of P.aeruginosa in this study was highest in 
surgery wards (54%) followed by medicine (18%) and orthopaedics wards 
(9%). A similar observation was made in a study by Angadi KM et al 
74
 and 
Prashant Durwas et al
61
.  
6.3. Distribution of Pseudomonas aeruginosa in clinical isolates: 
Most of the specimens collected in this study were pus from wound 
swab (72%) followed by sputum (19%), vaginal swab (4%) and urine (2%). 
A study by Mangaiarkkarasi et al 
75
 and Mahnaz saranghi et al
76
 showed that 
Pseudomonas aeruginosa were mostly isolated from the pus samples (59-
64%). Shammim mumtaz et al in their study obtained 7.3% of the 
Pseudomonas aeruginosa isolates from the vaginal swab
77
.  While the 
present study showed the isolation of Pseudomonas aeruginosa is more in 
pus there are other studies that showed the isolation was highest in 
specimens like broncho alveolar lavage (Behera et al
78
) and urine (V.javiya 
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et al
73
). This study indicates that the incidence of pyogenic infection is 
expected to be highest and was referred from surgical disciplines.  
6.4. Resistance pattern of antibiotics in Pseudomonas aeruginosa 
isolates: 
 About 90% of resistance was seen with cephalosporins like 
ceftriaxone and cefotaxime in this study.  In a study by Nagaveni et al there 
found 100% resistance to cephalosporins
79
. Many authors like Vikas kumar 
et al
64
, Yousef Irfani  et al
80
 and Mahnaz et al 
76
 have reported 52-70% of 
resistance towards cephalosporins in their study which is in contrast to the 
present study.  Resistance to fluoroquinolones against Ciprofloxacin and 
Ofloxacin were 71 and 52% respectively. The similar patterns of resistance 
to fluoroquinolones were reported in a study by Behera  et al
78
 and Bashir et 
al
8
. The resistance to aminoglycosides in the present study was 42% which 
is similar to the study by Saghir  et al
81
. Shanthi amudhan et al 
40
 in their 
study reported that 100% of the isolates were shown resistance to 
aminoglycosides and fluorquinolones which is not in line with the results of 
the current study. 
6.5. Screening for MBL production using Meropenem: 
 In the present study, by disc diffusion test 21% of the entire 
(100) Pseudomonas aeruginosa isolates were resistant to Meropenem 
(MRPA).  As the CLSI guidelines states that the Imipenem should not be 
used in the detection of carbapenemases, the Meropenem disc is used in this 
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study.  Deepa Bashir et al
8
 in their study reported that 13.42% of the entire 
isolates were resistant to Carbapenem.  Vikas kumar et al in their study 
stated that 19.4% of the Pseudomonas aeruginosa isolates were resistant to 
carbapenem
64
. The findings of the above study are consistent with the 
present study. Fatemeh fallah et al 
30
 reported 83% of the P.aeruginosa 
isolates and Horieh Saderi et al 
69 
reported 69% of P.aeruginosa isolates 
were resistant to Meropenem. The prevalence of resistant isolates was 
higher in the above studies. Horieh Saderi et al tends to conclude that the 
reasons for the variability of resistance rates of Meropenem in different 
studies were not clear though they suggest this difference may reveal the 
usage of antibiotics in various settings
69
. Similarly Ekta Gupta et al in their 
study argues that the resistance to the Meropenem was increased in a short 
period after the frequent use of the antibiotic in their clinical set up 
82
.  
6.6. Distribution of MRPA isolates according to site of infection: 
In the present study, 38.1% MRPA isolates were associated with 
wound infections, 14.5% of the isolates were from vaginitis and diabetic 
foot, 9.5% were associated with respiratory infections and 4.8% were from 
urinary tract infections. 
The study by Sasikala et al showed that MRPA was predominantly 
isolated from wound swabs (27%). Twenty per cent of the isolates were 
obtained from respiratory infections
83
. 43% of the isolates from diabetic foot 
were shown resistance to Imipenem in a study by Vinodkumar et al
84
. 
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In the present study the isolation of Meropenem resistant 
Pseudomonas aeruginosa was highly associated with surgical interventions 
like wound debridement, amputation and skin grafting.  
6.7. Phenotypic Detection of MBL: 
 In the present study three different phenotypic methods like CDT, 
DDST and MBL E test were used to detect the metallo beta lactamase 
production among the MRPA isolates.  (Behera et al.,
78
 2008; Lee et al.,
51
 
2003; Arakawa et al., 2000
72
).  
6.7.1. Combined disc test(CDT) and Double disc synergy test(DDST): 
 The present study shows that 14 out of 21 MRPA isolates (66.7%) 
were detected as MBL producer by the CDT.  
 Similar results were seen in a study done by Rajput et al that revealed 
66.7% of carbapenem resistant strains were MBL producer by CDT
16
. 
Jamshid Faghri et al in their study showed that CDT detected 42% of 
Meropenem resistant isolates produced MBL enzyme. This is in contrast 
with the present study results
85
. The prevalence rate in the above study is 
low when compared to the present study that may be due to difference in 
population size or sample size and also the health care practices followed in 
those areas. In various studies the MBL prevalence in P.aeruginosa isolates 
by CDT were ranging from 14-18% (Hemalatha et al., 2004
86
; Santhosh et 
al., 2010
87
; Rakesh et al., 2013
88
). Based on a study by Irfan et al, the CDT 
detected all the 25 carbapenem resistant isolates as MBL producer and 
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concluded that CDT can be considered as the screening method for the 
detection of MBL in the Carbapenem resistant isolates
89
. 
 The present study detected 12 out of 21 MRPA isolates (57.1%)  as 
MBL producers by DDST. A study done by Santhosh et al reported that 13 
out of 18 resistant isolates were MBL producers by DDST which is similar 
to our study results.
87
 While the present study has the prevalence of about 
55% among MRPA isolates, there are many studies which reported higher 
prevalence of about 70% (Agrawal et al.,
 62
 Fereshteh Shahcheraghi et al.,
37
 
and S.Aghamiri et al
90
). The dissimilarities in the stated results between the 
present study and those described above may be due to the difference in 
geographical regions, difference in kind of infections, the vast usage of 
antimicrobials, or difference in antibiotic policy in the particular hospitals in 
this study than those in other studies. 
6.7.2. MBL detection by E test: 
 The MBL E test using MP/MPI (Meropenem and Meropenem with 
EDTA) in this study detected 10 out of 21 MRPA isolates (47.6%) as MBL 
producer.  Manoharan et al in their study reported 42.6% among the 
carbapenem resistant isolates were positive for MBL production by E test
91
 
which is in agreement with the present study results.  In contrast to the 
present study, Bashir et al showed higher prevalence of MBL of about 86% 
of carbapenem resistant isolates were positive by the E test
8
.   
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6.8. Prevalence of blaVIM and blaIMP gene in the Meropenem resistant 
isolates: 
 The MBL production was detected in 10 out of 21 MRPA isolates 
(47.6%)   for the blaVIM gene by PCR in the present study. No blaIMP 
gene was detected in any of the isolates.  The genes other than blaVIM and 
blaIMP have not found beyond their place of origin and these genes were 
common all over the world
25
. Mariana Castanheira et al
38
,  Horieh Saderi et 
al
39
., M. Shanthi Amudhan et al 
40 
in their study concluded that the blaVIM 
gene was the most prevalent gene in Asia and India.   
 Horieh Saderi et al in their study detected 13% of isolates by PCR 
and only the VIM gene was identified and all of which were positive by 
phenotypic method. This is in similar with the present study results
39
. A 
study performed by Khosravi et al in a burn hospital in Iran, reported that all 
the 8 MBL positive strains contained the VIM gene and the IMP gene was 
not detected in any of the strains
92
.  The greater prevalence of the VIM gene 
than the IMP gene was revealed in a study by Pitout et al
29
 in which 1.6% of 
isolates was positive for IMP when compared to 43% of isolates that 
contained VIM gene.  In an another study by Mlynarczyk et al showed that 
the PCR detected 60% of the carbapenem resistant isolates as MBL 
producer and the gene isolated was blaVIM and it accounted for about 70% 
of the resistant isolates
93
. The prevalence in the above study was higher than 
the present study and the author concluded that there was an increase in the 
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prevalence from 7% in 2007 to 15% in 2008 and most of the MBLs 
belonged to the VIM type.  Aghamiri S et al in their study stated that 33% of 
the entire isolates were producing the MBL and the gene detected was 
blaVIM (33%) and blaIMP (9%). The author stated that the isolates 
negative for MBL gene by PCR may contain genes other than the VIM and 
IMP responsible for MBL production. The prevalence of VIM gene is more 
than the IMP gene which is similar to the present study
90
. The similar 
statements have been quoted in studies by Shanthi amudhan et al
40
, Sader 
HS et al
94
 and H. Saderi et al
39
. 
6.9. Comparison of Phenotypic methods with PCR in the detection of 
MBL: 
 Several phenotypic methods such as CDT, DDST and MBL E test are 
available for the detection of MBL producing Pseudomonas aeruginosa. 
Compared to PCR, the CDT shows the sensitivity and specificity of 90% 
and 55% respectively. 
 The result of the present study is in agreement with the study 
conducted by Manoharan et al that showed the sensitivity and specificity as 
87.8% and 53.3%, respectively when compared to the PCR
92
.  In a study 
from Johann D. D. Pitout et al, the CDT showed 100% sensitivity and 96% 
specificity
29
. The above study shows sensitivity similar to the present study 
but with the higher specificity.  
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 The DDST in the present study has the sensitivity and specificity of 
90% and 72% respectively when compared to PCR for MBL detection. 
 Bachunde et al, in Maharashtra, 2011 reported the sensitivity of the 
DDST in their study as 85.7% which is analogous to the present study
95
.  S 
John et al in their study stated that among the tests used for MBL detection 
DDST is more reliable to CDT and MHT
96
.  Yalda khosravi et al in their 
study reported that the specificity of DDST is higher when compared to 
CDT
97
. 
 The MBL E test has the sensitivity and specificity of 90% each. 
Similar results were obtained in the study done by Ting-ting Qu et al with 
sensitivity and specificity as 85.7% and 100% respectively
72
. Yalda kosravi 
et al in their study reported that the E test has given the sensitivity and 
specificity of 100% which is relatively similar to the current study
97
. 
Kyungon Lee et al in their study reported that the MBL E test is highly 
sensitive and specific for detecting blaIMP and blaVIM allele positive 
isolates of P.aeruginosa .
70
  
 Of the 21 MRPA isolates detected in the present study, the MBL 
producers by CDT and DDST were 14 and 12 respectively. The kappa value 
was low for CDT and moderate for DDST which denotes that the 
phenotypic tests were not effective in MBL detection. The same result has 
been reported in Franco MR et al
42
 Brazil and Fereshteh Shahcheraghi et al
 
37
. Those strains that were found negative by PCR were considered as false 
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positive using phenotypic test. The reason for the false positivity may be 
due to various mechanisms of EDTA such as 1) EDTA increases the 
membrane permeability that may increase the susceptibility to 
Meropenem.2) EDTA has bactericidal activity that increases the zone of 
inhibition to Carbapenems
42,41
 that were  not associated with the MBL 
production which would lead to false interpretation of the phenotypic tests.   
All the three phenotypic tests used in the present study gives the 
sensitivity rate of 90% but the specificity rate varies from 55-90%. The 
sensitivity and specificity for the MBL E test is 90%which is relatively 
more accurate in detecting the production of MBL when compared to the 
other phenotypic tests.  
In addition the MBL E test has the advantage over the other 
phenotypic tests, in that the minimum inhibitory concentration can be 
obtained which will be useful in the treatment of resistant pathogens. 
Despite the accuracy, the MBL E test is very costly to be used in the clinical 
laboratory for routine MBL screening procedure. Due to the cost constraints 
of the MBL E test a simple and cost effective method should be adopted. 
 The specificity of the DDST is comparatively more than CDT and 
hence DDST may be considered as a more suitable screening method used 
for the detection of MBL production in Pseudomonas aeruginosa. Those 
isolates positive by DDST can be further confirmed by the MBL E test if the 
PCR is not available in the settings of the clinical laboratory.   
99 
 
 In the present study not all Meropenem resistant isolates were found 
to be MBL producers. Similar results have been obtained in various studies 
such as Alexandre R. Marra et al
41
, Ami Varaiya et al
57
, Chacko  et al
98
, 
Ting ting Qu et al
72
 etc. This may be due to other mechanisms of resistance 
such as mutation in the outer membrane permeability, loss of porins or the 
upregulation of efflux systems.  Jose Manuel Rodriguez Martínez et al
99
, 
Elena Riera et a
100
, O. Gutierrez, C et al 
101 
have done studies to determine 
these resistance mechanisms other than MBL towards Carbapenem in the 
Pseudomonas aeruginosa isolates.  
6.10. Analysis of risk factors: 
6.10.1. Duration of hospital stay: 
 In the present study there is an association between the length of the 
hospital stay and isolation of MRPA strains. Most of the MRPA isolates 
were recovered from the patients who had a hospital stay of more than 2 
weeks. The mean hospital stay in the present study was 12.46 days. 
 In a study by Aloush et al, the average length of hospital stay was 17 
days among the patients with MRPA and most of the isolates were from 
wound infections which are concordant with the present study results
102
. 
Lautenbach et al in a study from two centres stated that the isolation of 
carbapenem resistant Pseudomonas aeruginosa was associated with longer 
hospital stay than with the susceptible strains
103
. This is in favour with the 
present study. Eva Morales et al in their study pointed out that the length of 
100 
 
stay (39.0 days) was longer among the patients with resistant Pseudomonas 
aeruginosa which was in accordance with the present study
104
.   
 The length of the hospital stay is considered as an important marker 
for the morbidity resulting from the infection. Hence the Meropenem 
resistant Pseudomonas aeruginosa can cause increased morbidity. 
6.10.2. Exposure to antibiotics: 
 Exposure to different classes of antibiotics in the patients harbouring 
MRPA and MSPA strains were analysed. Among these, antibiotics like third 
generation cephalosporins, aminoglycosides, fluoroquinolones, β lactamase 
+ β lactamase inhibitor combinations and carbapenems, exposure to third 
generation cephalosporins was statistically significant among corresponding 
MRPA patients.  
 Alexandre Prehn Zavascki et al stated in their study that the exposure 
to β-Lactam was an important risk factor for MBL production in 
Pseudomonas aeruginosa isolates
105
. 
6.11. Resistance pattern to antibiotics in MRPA:  
 All the MRPA isolates were resistant to third generation 
cephalosporins. In studies by Shanthi amudhan et al
40
 and Anuradha et al
106 
reported that the MRPA isolates were resistant to all antibiotics tested. The 
third generation cephalosporins are widely used in the community in the 
treatment of suspected Gram negative infections. This might have affected 
the susceptibility pattern towards the organism.  
101 
 
About 62% of the MRPA isolates were resistant to amikacin, 
gentamicin, ciprofloxacin and 50.6% were resistant to ofloxacin. Fereshteh 
Shahcheraghi et al also reported that most of the MBL producers were 
resistant to aminoglycosides and fluoroquinolones
37
.Since aminoglycosides 
were the antimicrobial agents most used in association with other antibiotics 
might be the cause for the resistance. 
6.12. Multi drug resistant Pseudomonas aeruginosa: 
 In the present study about 13 out of 21 MRPA isolates were 
multidrug resistant (MDRPA) i.e. resistant to any of the three classes of 
antibiotics 
45, 46
. Among the 13 MDRPA 8 were MBL producers. All the 
MDRPA were sensitive to the colistin and 53% of the MDRPA were 
susceptible to piperacillin-tazobactam and Cefaperazone sulbactam which 
correlates with the study done by Javiya et al
73
.   
 The rise in the prevalence of MBLs is creating a therapeutic challenge 
for clinicians and microbiologists. Screening for MBL production as a 
routine procedure in clinical laboratories with a simple screening test like 
DDST adds a valuable data to the clinician in appropriate selection of 
antibiotics and forms a crucial step in large scale monitoring of these 
emerging resistant strains. 
 The emergence of resistance to the antibiotics should be constantly 
monitored so that the antibiotic cycling policies and the occurrence of the 
newer resistance pattern in the hospital can be determined. There is also a 
102 
 
necessity to highlight on the rational use of antibiotics and strict adherence 
to the concept of reserve drugs to reduce the inappropriate use of the 
available antibiotics.  
 Various strategies like hand washing, environmental 
decontamination, education to the health care professionals and continuous 
surveillance will be helpful in attaining a goal of low level of infection with 
the multidrug resistant pathogens. The hospital infection control guidelines 
should be formulated strictly to avoid the future spread of these multi-drug 
resistant strains. 
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7. SUMMARY 
 
 In the present study the isolation of P.aeruginosa was more in the age 
group of 41-70 years. 
 The present study showed P.aeruginosa was isolated more in males 
(73%) than females (27%) with a male : female ratio of 2.7:1. 
 The rate of isolation of P.aeruginosa was highest in Surgery wards 
(54%). 
 The pus from wound swab constituted the majority of specimens 
accounting for 72% followed by sputum 19%, vaginal swab 4%, and 
urine 2%. 
 21% of the entire P.aeruginosa isolates were resistant to Meropenem 
(MRPA). 
 Majority of the MRPA infections were associated with wound 
infections (38.1%). 
 Most of the MRPA isolates were recovered from the patients who had 
a hospital stay of more than 2 weeks which is statistically significant.  
The mean hospital stay in the present study was 12.46 days.  
 Exposure to Cephalosporins was statistically significant among 
corresponding MRPA patients. 
104 
 
 Among the Pseudomonas aeruginosa isolates 10% were MBL 
producers by PCR. 
 The combined disc test(CDT) using Meropenem with EDTA as 
chelator detected 14(66.7%) isolates of MRPA as MBL producer. The 
test shows the Sensitivity 90%, Specificity 55%, PPV 64.2% and 
NPV85.7%.  
 The double disc synergy test(DDST) detected about 57.1% of the 
resistant isolates as MBL producers and the sensitivity, specificity, 
positive predictive value and negative predictive value of DDST for 
detecting MBL were 90%, 72%, 90% and 61% respectively. 
 The MBL E test in this study detected 47.6% of the resistant isolates 
as MBL producer and the sensitivity, specificity, positive predictive 
value and negative predictive value were 90% each. 
 The DDST is the simple, cost effective method in the detection of the 
MBL. 
 The E test is relatively accurate in the detection of MBL as close to 
the PCR. 
 All the MRPA isolates were resistant to third generation 
cephlosporins and about 62% of the MRPA isolates were resistant to 
Amikacin, Gentamicin, and Ciprofloxacin. 
105 
 
 In the present study 13 isolates were multidrug resistant(MDRPA) i.e 
resistant to any of the three classes of antibiotics and these isolates 
were sensitive to colistin which may be the drug of choice for the 
MDRPA isolates. 
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8. CONCLUSION 
 
 This study highlights the prevalence of MBL among various clinical 
isolates and also detects the presence of blaVIM and blaIMP gene 
among MRPA. 
 The MBL E test is very accurate in detecting the MBL as close to the 
PCR but with the cost constraints Double disc synergy test is very 
simple, easy and cost effective that can be easily adopted in the 
clinical laboratory. 
 Early detection of the MBL is crucial to include timely execution of 
strict infection control practices and treatment with alternative 
antimicrobials. 
 Good antibiotic policy, judicial use of antibiotics, hand hygiene and 
continuous surveillance will fight against the serious therapeutic 
challenges faced by the MBL Pseudomonas aeruginosa. 
 The colistin has become the last resort drug that can be used for the 
multidrug resistant Pseudomonas aeruginosa. 
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ANNEXURE – 1 
 
1. Nutrient agar medium: 
Composition 
Ingredients gram/liter 
Peptic digest of Animal Tissue 5.00 
Sodium Chloride 5.00 
Beef Extract 1.50 
Yeast Extract 1.50 
Agar 15.00 
Twenty-eight grams of dehydrated nutrient agar medium was added 
to 1000 ml of cold distilled water in a flask and boiled to dissolve the 
medium completely. The medium was then sterilized in an autoclave at 
121
0
C and 15 lbs pressure for 15 minutes. The sterile media were stored in a 
refrigerator at 4
0
C for future use. 
2. MacConkey agar medium: 
Composition - Ingredients gram/liter 
Peptone 19.0 
Lactose 10.0 
NaCl 5.0 
Na- Deoxycholate 1.0 
Neutral Red 0.03 
Crystal Violet 0.001 
Agar 15.0 
Fifty-two grams of dehydrated MacConkey agar medium was 
suspended in 1000 ml of cold distilled water and boiled to dissolve the 
medium completely. The solution was then sterilized by autoclaving at 
121
0
C and 15 lbs pressure for 15 minutes. 
3. Blood agar medium 
Composition 
Ingredients gram/liter 
Heart infusion 500.00 
Tryptose 10.00 
Sodium chloride 5.00 
Agar 15.00 
Forty grams of the dehydrated blood agar medium was suspended in 
1000 ml cold distilled water in a flask and boiled to dissolve the medium 
completely. It was then sterilized by autoclaving at 121
0
C and 15 lbs 
pressure for 15 minutes. The autoclaved materials were allowed to cool to a 
temperature of 45
0
C in a water bath. Defibrinated 5-10% sheep blood was 
then added to the medium aseptically and distributed to sterile petri dishes. 
Sterile media was stored in refrigerator at 4
0
C for future use. 
 
 
4. Muller Hinton agar medium 
Composition 
Ingredients gram/liter 
Beef dehytrated infusion 300 
Casein hydrolysate 17.50 
Starch agar 17.00 
Agar 17.00 
Thirty-eight grams of dehydrated Mueller Hinton agar medium was 
suspended in 1000 ml cold distilled water and boiled to dissolve the medium 
completely. The solution was then sterilized by autoclaving at 121
0
C and 15 
lbs pressure for 15 minutes. The autoclaved media was stored in the 
refrigerator and used later. 
5. McFarland Standard (0.5): 
Reagents: 
Sulphuric acid, 1%: To 100 ml of distilled water,1 ml of 
conc.sulphuric acid is added. Barium chloride, 1.175%: To 100 ml of 
distilled water, 1.175gm of barium chloride is added and mixed well.  
To prepare McFarland 0.5 standards: 
To 85 ml of 1% conc.sulphuric acid, 0.5 ml of Barium chloride is 
added in a flask while constantly swirling the flask. Bring to 100 ml with 
1% conc.sulphuric acid. Aliquot in test tubes and cap tubes tightly. Store in 
the dark at room temperature for 3 months or longer. 
PROFORMA 
Name    : 
Age    : 
Sex    : 
OP/IP No   : 
Lab No   : 
Ward    : 
Complaints   : 
Clinical diagnosis  : 
Nature of Specimen :  
Duration of hospital stay : 
Antibiotics administered : 
Investigation  : 
Biochemical tests  : Indole, Citrate, Urease, Triple sugar iron,  
  Catalase, Oxidase 
Antibiogram  : 
Piperacillin, Amikacin, Ceftriaxone, Cefotaxime, Ceftazidime, 
Ciprofloxacin, Ofloxacin, Gentamicin, Meropenam, Piperacillin with 
Tazobactam, Cefoperazone and sulbactam, Colistin.  
Screening test with meropenam 
Combined disc test  
Double disc synergy test 
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1 5129 63 F FS ABSCESS 18 PUS R R R R R R R R R S S S P P N N Y N N Y N IMPROVED
2 5185 45 M MS non healing ulcer 14 PUS S R S R S S S S S NA Y N Y N N IMPROVED
3 5198 41 M MS BURNS 10 PUS S S S S R S R S S NA Y N N N N IMPROVED
4 5254 45 M MS WOUND SEPSIS 14 PUS S R R R R S R R S NA N N N Y N IMPROVED
5 5269 60 M S Diabetic foot 16 PUS S R S R S S S S S NA Y N Y N N IMPROVED
6 5349 50 F S DM. Cellulitis 8 PUS S R R R R S R R S NA Y N N N N IMPROVED
7 5352 37 M M PNEUMONIA 7 SPUTUM S R R S R S R R S NA N Y Y N N IMPROVED
8 5354 67 F M PNEUMONIA 6 SPUTUM S R R R S S S S S NA Y N N N N IMPROVED
9 5496 60 M M WOUND INF 8 PUS S S S S S S R R S NA Y N Y N N IMPROVED
10 5818 57 M TB TB 7 SPUTUM S R R R R S S R S NA N N N Y N IMPROVED
11 5819 51 F TB TB 8 SPUTUM S R R S R S S S S NA Y N Y N N IMPROVED
12 5830 27 F LW PNEUMONIA 7 SPUTUM S R R R S S R S S NA Y N N N N IMPROVED
13 5836 55 M S DM 10 PUS S R R R R S R R S NA Y N N N N IMPROVED
14 5838 77 M S WOUND SEPSIS 14 PUS S S R S S S R R S NA Y N Y N N IMPROVED
15 5853 59 M S Necrotising fascitis 16 PUS R R R S S R R S R S S S P P P P Y N N N N IMPROVED
16 5844 45 M O WOUND SEPSIS 17 PUS R R R R S R R S R S S S N N N N N Y N N N IMPROVED
17 5986 50 M M PNEUMONIA 7 SPUTUM R R R S S R RR S S NA N N Y N N IMPROVED
18 5989 28 M O WOUND SEPSIS 12 PUS S R R R S S S S S NA Y N N N N IMPROVED
19 2933 2 M PICU SEPSIS 24 PUS R R R R S R R S R S S S N N N N N N Y N N IMPROVED
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20 6159 25 F LW PNEUMONIA 5 SPUTUM S R R R S R R S S NA Y N Y N N IMPROVED
21 6184 32 F LW VAGINITIS 17
VAGINALS
WAB
R R R R R R R R R S R R P P P P Y N N N N IMPROVED
22 6217 55 M M BRONCHIECTASIS 21 SPUTUM R R R S S R S S R S S S N N P P Y N N N N IMPROVED
23 6219 65 M S DIABETIC FOOT 20 PUS R R R R S R R S R S S S N N N N N N N N Y IMPROVED
24 6251 65 M S DIABETIC GANGRENE 21 PUS S R R S S R R S S NA Y N N N N IMPROVED
25 6242 11 M P.S ABSCESS 7 PUS R R R R S S R S S NA Y N N N N IMPROVED
26 6302 25 F LW PUO 16
VAGINALS
WAB
R R R R R R R R R S R R P P P P Y N Y N N IMPROVED
27 6314 40 M O1 WOUND SEPSIS 17 PUS R R R S S S R S S NA Y N N N N IMPROVED
28 6348 44 M M PNEUMONIA 16 SPUTUM R R R R R R R R R S S S P P N N Y N N N N IMPROVED
29 6359 49 M ENT CSOM 8
AURAL 
PUS
R R R R R R R R R S S S P P P P Y N Y N N IMPROVED
30 6360 29 M O infected fracture wound 19 PUS R R R R R R R R R S R R P P P P N N N N Y IMPROVED
31 6429 57 M O WOUND SEPSIS 17 PUS R R R R S R R S R S S S N N N N N N Y N N IMPROVED
32 6434 65 F FS DM. Cellulitis 14 PUS S R R R S S R R S NA Y N Y N N IMPROVED
33 6438 69 M S DM-Diabetic foot 13 PUS S R R S S R S R S NA Y N Y N N IMPROVED
34 6330 55 M S DM 16 PUS S R R R S S R R S NA N N Y N N IMPROVED
35 6333 58 M S BURNS 21 PUS S R R R S R R R S NA Y N Y N N IMPROVED
36 6614 44 M M PNEUMONIA 6 SPUTUM R R R R S R S R S NA Y N Y N N IMPROVED
37 8152 65 M U PROSTITIS 17 URINE R R R S S S R R R S S S N N N N N N Y N N IMPROVED
38 8360 32 F U UTI 6 URINE S R R S R R S S S NA Y N Y N N IMPROVED
39 13 25 F LW VAGINITIS 16
VAGINALS
WAB
R R R R S S S S R S S S N N N N Y N N N N IMPROVED
40 25 53 M M PLEURAL EFFUSION 15
PLEURAL 
FLUID
R R R R S S R S S NA Y N Y N N IMPROVED
41 55 2 M M HYDROCEPHALUS 14 CSF S R R S R R R R S NA N Y Y N N IMPROVED
42 56 20 M S BURNS 18 PUS S R R S R R S S S NA Y N Y N N IMPROVED
43 98 69 M S DM 21 PUS R R R R R R R R R S S S P N N N N N Y N N IMPROVED
44 122 60 M O WOUND SEPSIS 20 PUS S R R S S S R S S NA Y N Y N N IMPROVED
45 124 28 F O WOUND SEPSIS 17 PUS R R R R R R R R R S S S P P P P N N N N Y IMPROVED
46 132 70 F S DM 15 PUS R R R R R R R R R S R R P P P P N N Y N N IMPROVED
47 134 12 M ENT CSOM 6 PUS S R R R S S R S S NA Y N N N N IMPROVED
48 190 75 M S PNUMONITIS 5 SPUTUM S R R S R S R R S NA Y N Y N N IMPROVED
49 203 68 M S PYOCELE 21 PUS S R R R S R R S S NA N N Y N N IMPROVED
50 217 60 F S ABSCESS 7 PUS S R R S R S S R S NA Y Y N N N IMPROVED
51 277 55 M M PNEUMONIA 8 SPUTUM S R R R S R R S S NA Y N N N N IMPROVED
52 298 30 M S WOUND SEPSIS 15 PUS R R R R R R R R R S S S P P P P N N Y N N IMPROVED
53 333 73 M LEP WOUND SEPSIS 14 PUS S R R R S S R S S NA Y N Y N N IMPROVED
54 337 65 F S DM 12 PUS S R R S R S R S S NA Y N N N N IMPROVED
55 345 12 F ChS SSI 18 PUS S R R R S R S R S NA Y N Y N N IMPROVED
56 368 68 M S colostomy drain infetion 15 PUS S R R R S R R S S NA N Y N N N IMPROVED
57 395 40 F S WOUND SEPSIS 14 PUS S R R R R S R R S NA Y N Y N N IMPROVED
58 403 70 M S WOUND SEPSIS 17 PUS S R R R S S S R S NA Y N N Y N IMPROVED
59 404 45 M S WOUND SEPSIS 18 PUS S R R R R R R R S NA Y N N N N IMPROVED
60 408 35 F S post op wound infection 10 PUS S R R R S R R R S NA Y N N N N IMPROVED
61 420 61 M M PNUMONIA 8 SPUTUM S R R S R S R S S NA N N Y N N IMPROVED
62 429 55 M S WOUND SEPSIS 10 PUS S R R R S R R S S NA Y N N N N IMPROVED
63 483 9 F ChS WOUND SEPSIS 10 PUS S R R R R S S S S NA Y N Y N N IMPROVED
64 497 80 M S WOUND SEPSIS 13 PUS S R R R S R R S S NA Y N N Y N IMPROVED
65 526 45 F S WOUND SEPSIS 12 PUS S R R R R S R S S NA Y N N N N IMPROVED
66 537 27 M O INFECTED FRACTURE 17 PUS S S R R S S S R S NA Y N Y Y N IMPROVED
67 545 60 M S WOUND SEPSIS 11 PUS S S R S S S R S S NA N N N Y Y IMPROVED
68 554 60 M M PNEUMONIA 9 SPUTUM S R R R R R R R S NA Y N Y N N IMPROVED
69 558 42 M M PNEUMONIA 8 SPUTUM S S R R S S R R S NA Y N N N N IMPROVED
70 570 65 M S WOUND SEPSIS 12 PUS S S R R S R S S S NA Y N N Y N IMPROVED
71 640 70 M S PYOCELE 17 PUS R R R R R R R R R R R R P P N N N N Y N N IMPROVED
72 668 65 M S WOUND SEPSIS 20 PUS R R R R R R R R R R S S P N N N N Y N N N IMPROVED
73 694 37 F ENT CSOM 10 PUS R R R R R R R R R R R R P P P P N N Y N N IMPROVED
74 736 39 M S WOUND SEPSIS 8 PUS S R R S S S S S S NA Y N N N N IMPROVED
75 743 34 F LW PNUMONIA 5 SPUTUM S R R R R S R S S NA Y N N N N IMPROVED
76 747 19 F BURNS BURNS 5 PUS S R R R S S S S S NA N Y Y N N IMPROVED
77 761 70 M S WOUND SEPSIS 15 PUS S R R R S S S S S NA Y N N N N IMPROVED
78 818 60 M S WOUND SEPSIS 16 PUS S R R R R S R R S NA Y N Y N N IMPROVED
79 875 59 M S WOUND SEPSIS 21 PUS S R R R S S R R S NA Y N N N N IMPROVED
80 904 39 M CAS ABSCESS 6 PUS S R R R S S R R S NA N N N Y Y IMPROVED
81 909 75 F S DIABETIC FOOT 8 PUS S R R R S R S S S NA Y N Y N N IMPROVED
82 915 28 M CAS ABSCESS 5 PUS S R R R R S R R S NA Y N Y N N IMPROVED
83 917 35 M S WOUND SEPSIS 7 PUS S R R S S R R R S NA Y N N N N IMPROVED
84 951 39 M CAS ABSCESS 5 PUS S R R R S S S R S NA Y N Y N N IMPROVED
85 977 55 M S WOUND SEPSIS 13 PUS S R R R S R R S S NA N N N N N IMPROVED
86 996 55 M S WOUND SEPSIS 17 PUS S R R R R S R S S NA Y N N N N IMPROVED
87 1064 67 M M PNEUMONIA 7 SPUTUM S R R R R S R R S NA Y N Y N N IMPROVED
88 1078 40 M ORTHO WOUND SEPSIS 12 PUS S R R R S S S S S NA N N Y N N IMPROVED
89 1138 54 M M COPD 15 SPUTUM S R R R S R R R S NA Y N N N N IMPROVED
90 1184 35 F S PNEUMONIA 11 SPUTUM S R R R R S R R S NA Y N Y N N IMPROVED
91 1203 86 M M DM 18 PUS S R R R S S S R S NA Y N N Y N IMPROVED
92 1145 29 M S BURNS 4 PUS S R R S S R S S S NA Y N Y N N IMPROVED
93 1153 35 F S DM 13 PUS S R R R R S R R S NA N N Y N N IMPROVED
94 1167 35 M S ABSCESS 6 PUS S R R S S R R R S NA Y N N N N IMPROVED
95 1205 65 M S DM 7 PUS S R R S R S R R S NA N N N N N IMPROVED
96 1228 62 F LW VAGINITIS 5
VAGINALS
WAB
S R R S S S S S S NA Y N N N N IMPROVED
97 1287 59 M BURNS BURNS 8 PUS S R R S R S R S S NA Y N Y N N IMPROVED
98 1300 27 M S WOUND SEPSIS 9 PUS S R R S S S R R S NA N N N Y N IMPROVED
99 1319 65 M S WOUND SEPSIS 12 PUS S R R S R S S S S NA Y N N N N IMPROVED
100 1367 47 M S WOUND SEPSIS 15 PUS S R R S S R R R S NA Y N N N N IMPROVED
